Accuray (ARAY) 10-Q 29 Apr 22 2022 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Mar. 31, 2022	Apr. 18, 2022
Cover [Abstract]
Entity Registrant Name	ACCURAY INCORPORATED
Entity Central Index Key	0001138723
Document Type	10-Q
Document Period End Date	Mar. 31, 2022
Amendment Flag	false
Current Fiscal Year End Date	--06-30
Entity Current Reporting Status	Yes
Trading Symbol	ARAY
Entity Filer Category	Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		92,802,213
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q3
Entity File Number	001-33301
Entity Tax Identification Number	20-8370041
Entity Address, Address Line One	1310 Chesapeake Terrace
Entity Address, City or Town	Sunnyvale
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94089
City Area Code	408
Local Phone Number	716-4600
Entity Incorporation, State or Country Code	DE
Entity Interactive Data Current	Yes
Document Quarterly Report	true
Document Transition Report	false
Title of 12(b) Security	Common Stock, $0.001 par value per share
Security Exchange Name	NASDAQ

Unaudited Condensed Consolidate

Unaudited Condensed Consolidated Balance Sheets - USD ($) $ in Thousands		Mar. 31, 2022	Dec. 31, 2021	Jun. 30, 2021
Current assets:
Cash and cash equivalents		$ 97,839		$ 116,369
Restricted cash		205		560
Accounts receivable, net of allowance for credit losses of $1,058 and $1,048 as of March 31, 2022 and June 30, 2021, respectively	[1]	89,295		85,360
Inventories		137,519		125,929
Prepaid expenses and other current assets	[2]	21,987		21,547
Deferred cost of revenue		351		3,008
Total current assets		347,196		352,773
Property and equipment, net		12,220		12,332
Investment in joint venture		14,251		15,935
Operating lease right-of-use assets, net		17,851		22,522
Goodwill		58,000		57,960
Intangible assets, net		286		435
Restricted cash		1,244		1,272
Other assets		18,388		16,869
Total assets		469,436		480,098
Current liabilities:
Accounts payable		32,364		19,467
Accrued compensation		25,461		26,865
Operating lease liabilities, current		8,351		8,169
Other accrued liabilities		26,018		27,471
Customer advances		24,363		24,937
Deferred revenue		76,732		81,660
Short-term debt		8,051		3,790
Total current liabilities		201,340		192,359
Long-term liabilities:
Operating lease liabilities, non-current		11,929		17,441
Long-term other liabilities		6,812		7,766
Deferred revenue		24,550		23,685
Long-term debt		173,196		170,007
Total liabilities		417,827		411,258
Commitments and contingencies (Note 9)
Stockholders' equity:
Common stock, $0.001 par value; authorized: 200,000,000 shares as of March 31, 2022 and June 30, 2021, respectively; issued and outstanding: 92,802,213 and 90,821,661 shares at March 31, 2022 and June 30, 2021, respectively		93		91
Additional paid-in-capital		539,383		554,680
Accumulated other comprehensive income		1,203		2,093
Accumulated deficit		(489,070)		(488,024)
Total stockholders' equity		51,609	$ 50,994	68,840
Total liabilities and stockholders' equity		$ 469,436		$ 480,098
[1]	Includes trade receivable from the China joint venture, an equity method invest ment of $ 24,146 and $ 8,822 at March 31, 2022 and June 30, 2021, respectively. See Note 14.
[2]	Includes other receivable from the China joint venture, an equity method investment of $ 616 and $ 187 at March 31, 2022 and June 30, 2021, respectively.

Unaudited Condensed Consolida_2

Unaudited Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2022	Jun. 30, 2021
Accounts receivable, allowance for credit losses (in dollars)	$ 1,058	$ 1,048
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, authorized shares	200,000,000	200,000,000
Common stock, issued shares	92,802,213	90,821,661
Common stock, outstanding shares	92,802,213	90,821,661
Accounts receivable from joint venture	$ 24,146	$ 8,822
Prepaid Expenses and Other Current Assets
Accounts receivable from joint venture	$ 616	$ 187

Unaudited Condensed Consolida_3

Unaudited Condensed Consolidated Statements of Operations and Comprehensive Income - USD ($) shares in Thousands, $ in Thousands		3 Months Ended		9 Months Ended
		Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Net revenue:
Total net revenue		$ 96,169	$ 102,562	$ 319,886	$ 285,353
Cost of revenue:
Total cost of revenue	[1]	61,385	63,020	202,951	169,577
Gross profit		34,784	39,542	116,935	115,776
Operating expenses:
Research and development	[2]	14,104	13,268	43,183	37,372
Selling and marketing		10,798	10,567	35,302	29,813
General and administrative		10,174	11,281	32,350	30,498
Total operating expenses		35,076	35,116	110,835	97,683
Income (loss) from operations		(292)	4,426	6,100	18,093
Income (loss) on equity method investment, net		1,946	(68)	774	1,021
Other expense, net		(2,293)	(4,027)	(7,451)	(12,981)
Income (loss) before provision for income taxes		(639)	331	(577)	6,133
Provision for income taxes		407	721	1,318	1,352
Net income (loss)		$ (1,046)	$ (390)	$ (1,895)	$ 4,781
Net income (loss) per share - basic		$ (0.01)	$ 0	$ (0.02)	$ 0.05
Net income (loss) per share - diluted		$ (0.01)	$ 0	$ (0.02)	$ 0.05
Weighted average common shares used in computing net income per share:
Basic		92,761	93,123	91,780	92,106
Diluted		92,761	93,123	91,780	93,422
Net income		$ (1,046)	$ (390)	$ (1,895)	$ 4,781
Foreign currency translation adjustment		(1,013)	(2,102)	(890)	1,199
Comprehensive income (loss)		(2,059)	(2,492)	(2,785)	5,980
Products
Net revenue:
Total net revenue	[3]	43,198	47,439	156,678	120,502
Cost of revenue:
Total cost of revenue		28,371	27,709	95,400	69,237
Services
Net revenue:
Total net revenue	[4]	52,971	55,123	163,208	164,851
Cost of revenue:
Total cost of revenue		$ 33,014	$ 35,311	$ 107,551	$ 100,340
[1]	Includes cost of revenue from sales to the China joint venture, an equity method investment of $ 14,838 and $ 29,086 for the three and nine months ended March 31, 2022 and $ 2,387 and $ 7,088 for the three and nine months ended March 31, 2021, respectively .
[2]	Includes chargeback to the China joint venture, an equity method investment related to research and development project of $ 549 and $ 1,543 for the three and nine months ended March 31, 2022 $ 0 and $ 430 for the three and nine months ended March 31, 2021 .
[3]	Includes sales to the China joint venture, an equity method investment of $ 17,442 and $ 32,177 for the three and nine months ended March 31, 2022 and $ 1,633 and $ 5,954 for the three and nine months ended March 31, 2021, respectively. See Note 14.
[4]	Includes sales to the China joint venture, an equity method investment of $ 2,326 and $ 7,820 for the three and nine months ended March 31, 2022 and $ 4,934 and $ 10,197 for the three and nine months ended March 31, 2021, respectively. See Note 14.

Unaudited Condensed Consolida_4

Unaudited Condensed Consolidated Statements of Operations and Comprehensive Income (Parenthetical) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
		Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Total net revenue		$ 96,169	$ 102,562	$ 319,886	$ 285,353
Total cost of revenue	[1]	61,385	63,020	202,951	169,577
Research and development	[2]	14,104	13,268	43,183	37,372
Products
Total net revenue	[3]	43,198	47,439	156,678	120,502
Total cost of revenue		28,371	27,709	95,400	69,237
Services
Total net revenue	[4]	52,971	55,123	163,208	164,851
Total cost of revenue		33,014	35,311	107,551	100,340
Revenue from Joint Venture
Total cost of revenue		14,838	2,387	29,086	7,088
Research and development		549	0	1,543	430
Revenue from Joint Venture | Products
Total net revenue		17,442	1,633	32,177	5,954
Revenue from Joint Venture | Services
Total net revenue		$ 2,326	$ 4,934	$ 7,820	$ 10,197
[1]	Includes cost of revenue from sales to the China joint venture, an equity method investment of $ 14,838 and $ 29,086 for the three and nine months ended March 31, 2022 and $ 2,387 and $ 7,088 for the three and nine months ended March 31, 2021, respectively .
[2]	Includes chargeback to the China joint venture, an equity method investment related to research and development project of $ 549 and $ 1,543 for the three and nine months ended March 31, 2022 $ 0 and $ 430 for the three and nine months ended March 31, 2021 .
[3]	Includes sales to the China joint venture, an equity method investment of $ 17,442 and $ 32,177 for the three and nine months ended March 31, 2022 and $ 1,633 and $ 5,954 for the three and nine months ended March 31, 2021, respectively. See Note 14.
[4]	Includes sales to the China joint venture, an equity method investment of $ 2,326 and $ 7,820 for the three and nine months ended March 31, 2022 and $ 4,934 and $ 10,197 for the three and nine months ended March 31, 2021, respectively. See Note 14.

Unaudited Condensed Consolida_5

Unaudited Condensed Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Cumulative adjustment due to adoption of ASU No. 2020-06	Common Stock	Additional Paid-in Capital	Additional Paid-in CapitalCumulative adjustment due to adoption of ASU No. 2020-06	Accumulated Other Comprehensive Income / (Loss)	Accumulated Deficit	Accumulated DeficitCumulative adjustment due to adoption of ASU No. 2020-06
Balance at Jun. 30, 2020	$ 63,635		$ 91	$ 545,741		$ (484)	$ (481,713)
Balance (in shares) at Jun. 30, 2020			91,178,108
Issuance of restricted stock (in shares)			95,575
Share-based compensation	1,910			1,910
Net income	402						402
Cumulative translation adjustment	1,493					1,493
Balance at Sep. 30, 2020	67,440		$ 91	547,651		1,009	(481,311)
Balance (in shares) at Sep. 30, 2020			91,273,683
Balance at Jun. 30, 2020	63,635		$ 91	545,741		(484)	(481,713)
Balance (in shares) at Jun. 30, 2020			91,178,108
Net income	4,781
Cumulative translation adjustment	1,199
Balance at Mar. 31, 2021	78,550		$ 93	554,673		716	(476,932)
Balance (in shares) at Mar. 31, 2021			93,260,654
Balance at Sep. 30, 2020	67,440		$ 91	547,651		1,009	(481,311)
Balance (in shares) at Sep. 30, 2020			91,273,683
Exercise of stock options, net	66			66
Exercise of stock options, net (in shares)			17,175
Issuance of restricted stock	(343)			(343)
Issuance of restricted stock (in shares)			1,117,816
Issuance of common stock under employee stock purchase plan	1,042		$ 1	1,041
Issuance of common stock under employee stock purchase plan (in shares)			580,663
Share-based compensation	2,995			2,995
Net income	4,769						4,769
Cumulative translation adjustment	1,809					1,809
Balance at Dec. 31, 2020	77,778		$ 92	551,410		2,818	(476,542)
Balance (in shares) at Dec. 31, 2020			92,989,337
Exercise of stock options, net	790		$ 1	789
Exercise of stock options, net (in shares)			191,833
Issuance of restricted stock (in shares)			79,484
Share-based compensation	2,474			2,474
Net income	(390)						(390)
Cumulative translation adjustment	(2,102)					(2,102)
Balance at Mar. 31, 2021	78,550		$ 93	554,673		716	(476,932)
Balance (in shares) at Mar. 31, 2021			93,260,654
Balance at Dec. 31, 2021	50,994		$ 93	536,709		2,216	(488,024)
Balance (in shares) at Dec. 31, 2021			92,733,531
Balance at Jun. 30, 2021	$ 68,840	$ (24,784)	$ 91	554,680	$ (25,633)	2,093	(488,024)	$ 849
Balance (in shares) at Jun. 30, 2021	90,821,661		90,821,661
Issuance of restricted stock (in shares)			97,315
Share-based compensation	$ 2,506			2,506
Net income	(1,028)						(1,028)
Cumulative translation adjustment	231					231
Balance at Sep. 30, 2021	45,765		$ 91	531,553		2,324	(488,203)
Balance (in shares) at Sep. 30, 2021			90,918,976
Balance at Jun. 30, 2021	$ 68,840	$ (24,784)	$ 91	554,680	$ (25,633)	2,093	(488,024)	$ 849
Balance (in shares) at Jun. 30, 2021	90,821,661		90,821,661
Net income	$ (1,895)
Cumulative translation adjustment	(890)
Balance at Mar. 31, 2022	$ 51,609		$ 93	539,383		1,203	(489,070)
Balance (in shares) at Mar. 31, 2022	92,802,213		92,802,213
Balance at Sep. 30, 2021	$ 45,765		$ 91	531,553		2,324	(488,203)
Balance (in shares) at Sep. 30, 2021			90,918,976
Exercise of stock options, net	1,224		$ 1	1,223
Exercise of stock options, net (in shares)			331,401
Issuance of restricted stock	(258)			(258)
Issuance of restricted stock (in shares)			1,061,356
Issuance of common stock under employee stock purchase plan	1,524		$ 1	1,523
Issuance of common stock under employee stock purchase plan (in shares)			421,798
Share-based compensation	2,668			2,668
Net income	179						179
Cumulative translation adjustment	(108)					(108)
Balance at Dec. 31, 2021	50,994		$ 93	536,709		2,216	(488,024)
Balance (in shares) at Dec. 31, 2021			92,733,531
Issuance of restricted stock (in shares)			68,682
Share-based compensation	2,674			2,674
Net income	(1,046)						(1,046)
Cumulative translation adjustment	(1,013)					(1,013)
Balance at Mar. 31, 2022	$ 51,609		$ 93	$ 539,383		$ 1,203	$ (489,070)
Balance (in shares) at Mar. 31, 2022	92,802,213		92,802,213

Unaudited Condensed Consolida_6

Unaudited Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Cash flows from operating activities
Net income (loss)	$ (1,895)	$ 4,781
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	4,244	4,892
Share-based compensation	7,911	7,097
Amortization of debt issuance costs	594	1,086
Accretion of interest on debt	0	3,757
Provision for credit losses	241	78
Non-cash revenue transactions related to joint venture contribution	0	(1,365)
Provision for write-down of inventories	2,826	4,553
Loss on disposal of property and equipment	28	62
Income on equity method investment	(774)	(1,021)
Release (deferral) of equity method investment intra-entity profit on sales	3,559	(185)
Changes in assets and liabilities:
Accounts receivable	(4,611)	22,202
Inventories	(15,854)	(7,007)
Prepaid expenses and other assets	(2,656)	618
Deferred cost of revenue	2,657	1,272
Accounts payable	13,013	(5,028)
Operating lease liabilities, net	(666)	(473)
Accrued liabilities	(3,366)	693
Customer advances	(326)	710
Deferred revenues	(2,681)	(4,405)
Net cash provided by operating activities	2,244	32,317
Cash flows from investing activities
Purchases of property and equipment	(3,321)	(1,427)
Additional investments in joint venture	0	(79)
Net cash used in investing activities	(3,321)	(1,506)
Cash flows from financing activities
Proceeds from employee stock plans	1,224	1,042
Proceeds from exercise of options	1,524	855
Taxes paid related to net share settlement of equity awards	(258)	(343)
Paydown under the Company's prior term loan and amendment cost, net	0	(10,500)
Paydown under Term Loan	(3,000)	0
Repayments under the Company's prior revolving credit facility, net	0	(447)
Repayments under Revolving Credit Facility, net	(15,000)	0
Net cash used in financing activities	(15,510)	(9,393)
Effect of exchange rate changes on cash, cash equivalents and restricted cash	(2,326)	127
Net increase (decrease) in cash, cash equivalents and restricted cash	(18,913)	21,545
Cash, cash equivalents and restricted cash at beginning of period	118,201	109,911
Cash, cash equivalents and restricted cash at end of period	99,288	131,456
Supplemental disclosures of cash flow information:
Write-off of previously reserved accounts receivable	0	3,617
Reclassification of equity component of convertible notes into liabilities upon adoption of ASU 2020-06	$ 25,633	$ 0

The Company and its Significant

The Company and its Significant Accounting Policies	9 Months Ended
	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
The Company and its Significant Accounting Policies	Note 1. The Company and its Significant Accounting Policies The Company Accuray Incorporated (together with its subsidiaries, the “Company” or “Accuray”) designs, develops and sells advanced radiosurgery and radiation therapy systems for the treatment of tumors throughout the body. The Company is incorporated in Delaware and has its principal place of business in Sunnyvale, California. The Company has primary offices in the United States, Switzerland, China, Hong Kong and Japan and conducts its business worldwide. Basis of Presentation The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant inter-company transactions and balances have been eliminated in consolidation. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (“GAAP”), pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Certain information and note disclosures have been condensed or omitted pursuant to such rules and regulations. The unaudited condensed consolidated financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for a fair presentation of the periods presented. The results for the three and nine months ended March 31, 2022 are not necessarily indicative of the results to be expected for the fiscal year ending June 30, 2022, or for any other future interim period or fiscal year. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and accompanying notes for the fiscal year ended June 30, 2021 included in the Company’s Annual Report on Form 10-K filed with the SEC on August 17, 2021. Risks and Uncertainties The Company is subject to risks and uncertainties as a result of a novel strain of coronavirus, severe acute respiratory syndrome coronavirus 2, or SARS-CoV-2, which causes coronavirus disease 2019 (“COVID-19”) and has resulted in a worldwide pandemic. The extent of the impact of the COVID-19 pandemic on the Company's business is highly uncertain and difficult to predict, as the effects of and response to the pandemic are rapidly evolving and new information is regularly coming to light, particularly as new COVID-19 variants emerge. The Company's customers are diverting resources to treat COVID-19 patients and deferring non-urgent and elective procedures. Some customers, which include hospitals, major academic medical centers, and other related entities, have incurred significant losses during the COVID-19 pandemic due to reduced patient volume. These impacts on the Company's customers may adversely affect their ability to meet their financial and other contractual obligations, including to the Company. Furthermore, global economic uncertainty, including labor shortages and disruptions in the global supply chain, related to the COVID-19 pandemic may result in an incremental adverse impact on revenue, net income (loss) and cash flow and may require significant additional expenditures or cost-cutting to mitigate such impacts. Policymakers around the globe have responded with fiscal policy actions to support the healthcare industry and economy as a whole. The magnitude and overall effectiveness of these actions remain uncertain. The Company’s financial results have also been affected by the COVID-19 pandemic in various ways. The COVID-19 pandemic is adversely impacting the pace at which the Company’s backlog converts to revenue. This is primarily the result of pandemic-related delays in the timing of deliveries and installations, which has adversely affected our revenue. The Company has experienced such delays in deliveries and installations since the third quarter of fiscal year 2020 and expects that such delays in will continue at least through the end of the calendar year of 2022, if not longer, which could have a negative impact on revenue. The Company has experienced disruptions in its sales cycle as well as delays in customer payments and service agreements. The Company has also received requests from a few customers to extend payment terms or temporarily suspend service and corresponding payment obligations. While the Company has only received a small number of requests thus far, there can be no guarantee that more customers will not ask for the same in the future. In addition, as the COVID-19 pandemic continues to impact the global supply chain, disruptions in parts of our supply chain have resulted in delays in the receipt of certain components for our products as well as increased pricing pressure for such parts. These ongoing supply chain challenges and heightened logistics costs have adversely affected the Company's gross margins and net income (loss), and the Company’s current expectations are that gross margins and net income (loss) will continue to be adversely affected by increased material costs and freight and logistic expenses through at least the remainder of the calendar year of 2022, if not longer. Furthermore, certain parts required for the manufacture and servicing of the Company's products, such as electronic components, are scarce and becoming increasingly difficult to source even at increased prices. If such parts become unavailable to the Company, it would not be able to manufacture or service our products, which would adversely impact revenue, gross margins, and net income (loss). As a result, the Company is carefully monitoring the pandemic and the potential length and depth of the resulting economic impact on our financial condition and results of operations. There remain uncertainties around the spread, severity and potential resurgence of COVID-19, the impact of new COVID-19 variants, vaccination deployment efforts, and how long the pandemic and associated health measures will last, the related financial impact cannot be reasonably estimated at this time, although the impacts are expected to continue and may significantly affect the Company’s business. The Company continues to critically review its liquidity and anticipated capital requirements in light of the significant uncertainty created by the COVID-19 pandemic. Based on the Company’s cash and cash equivalents balance, available debt facilities, current business plan and revenue prospects, the Company believes that it will have sufficient cash resources and anticipated cash flows to fund its operations for at least the next 12 months. However, the Company is unable to predict with certainty the impact of the COVID-19 pandemic, including its effect on global supply chain and logistics, will have on its ability to maintain compliance with the debt covenants contained in the credit agreement related to its Credit Facilities (as such terms are defined in Note 10 below), including financial covenants regarding the consolidated fixed charge coverage ratio and consolidated senior net leverage ratio. The Company was in compliance with such covenants at March 31, 2022. Failure to meet the covenant requirements in the future could cause the Company to be in default and the maturity of the related debt could be accelerated and become immediately payable. This may require the Company to obtain waivers or amendments to the credit agreement in order to maintain compliance and there can be no certainty that any such waiver or amendment will be available, or what the cost of such waiver or amendment, if obtained, would be. If the Company is unable to obtain necessary waivers or amendment and the debt under such credit facility is accelerated, the Company would be required to obtain replacement financing at prevailing market rates, which may not be favorable to the Company. There is no guarantee that the Company would be able to satisfy its obligations if any of its indebtedness is accelerated. Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and related disclosures at the date of the financial statements. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts of the COVID-19 pandemic. Key estimates and assumptions made by the Company relate to revenue recognition and the assessment of stand-alone selling price (“SSP”), assessment of recoverability of goodwill and intangible assets, valuation of our equity method investment in the JV, valuation of inventories, annual performance related bonuses, allowance for credit losses and loss contingencies. Actual results could differ materially from those estimates. Significant Accounting Policies Other than the policy adoption discussed below under Accounting Pronouncements Recently Adopted, there have been no changes in the Company’s significant accounting policies during the nine months ended March 31, 2022 compared to the significant accounting policies described in its Annual Report on Form 10-K for the fiscal year ended June 30, 2021 .

Recent Accounting Pronouncement

Recent Accounting Pronouncements	9 Months Ended
	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Recent Accounting Pronouncements	Note 2. Recent Accounting Pronouncements Accounting Pronouncement Recently Adopted In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying Accounting for Income Taxes (“ASU 2019-12”). The amendments in ASU 2019-12 are intended to simplify various aspects related to accounting for income taxes and reduce the cost of accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. The Company adopted ASU 2019-12 on July 1, 2021. The adoption of this standard did not have a material impact on its consolidated financial statements. In January 2020, the FASB issued ASU 2020-01 Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815) - Clarifying the Interactions between Topic 321, Topic 323, and Topic 815. This guidance addresses accounting for the transition into and out of the equity method and provides clarification of the interaction of rules for equity securities, the equity method of accounting, and forward contracts and purchase options on certain types of securities. This standard is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2020. The Company adopted ASU 2020-01 on July 1, 2021. The adoption of this standard did not have a material impact on its consolidated financial statements. In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) No. 2020-06 , Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40). Under ASU No. 2020-06, the embedded conversion features are no longer separated from the host contract for convertible instruments with conversion features that are not required to be accounted for as derivatives under Topic 815, or that do not result in substantial premiums accounted for as paid-in capital. Consequently, a convertible debt instrument will be accounted for as a single liability measured at its amortized cost, as long as no other features require bifurcation and recognition as derivatives. The new guidance also requires the if-converted method to be applied for all convertible instruments when calculating diluted earnings per share. The Company adopted this standard effective July 1, 2021, using a modified retrospective method, under which financial results reported in prior periods were not adjusted. The Company applied the provisions of this guidance to our 3.75 % convertible senior notes due June 2026 (“2026 Notes”). Upon adoption, the Company recorded an increase to Accumulated deficit of $ 0.8 million, a decrease to Additional paid-in capital of $ 25.6 million and an increase to Debt of $ 24.8 million. There was no impact to diluted loss per share as the inclusion of potential shares of common stock related to the 2026 Notes would have been anti-dilutive. For further information, see Note 10, Debt. In October 2020, the FASB issued ASU 2020-10, Codification Improvements - Disclosures. This ASU improves consistency by amending the codification to include all disclosure guidance in the appropriate disclosure sections and clarifies application of various provisions in the codification by amending and adding new headings, cross referencing to other guidance, and refining or correcting terminology. This ASU is effective for fiscal years beginning after December 15, 2020. This ASU will not affect the Company's results of operations, cash flows or financial position. The adoption of ASU No. 2020-10 by the Company effective July 1, 2021 did not have a material impact on the Company’s financial statements or disclosures. Accounting Pronouncements Not Yet Effective In March 2020, the FASB issued an update (“ASU 2020-04”) establishing Accounting Standards Codification (“ASC”) Topic 848, Reference Rate Reform. ASU 2020-04 contains practical expedients for reference rate reform related activities that impact debt, leases, derivatives and other contracts. The guidance in ASU 2020-04 is optional and may be elected over time as reference rate reform activities occur. The Company’s Term Loan Facility and Revolving Credit Facility applies Eurodollar rate LIBOR to the variable component of the interest rate, if a Benchmark transition event, or an early opt-in election, as applicable occurred a transition to the use of the Secured Overnight Financing Rate ("SOFR") to replace such rate. The Company is currently evaluating the impact of the guidance and our options related to the practical expedients. In October 2021, the FASB issued ASU No. 2021-08, Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. The amendment addresses how to account for contract assets recognized under Topic 606 in a business combination. This standard is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2022. The Company is currently evaluating the impact ASU 2021-08 will have on its financial statements.

Revenue

Revenue	9 Months Ended
	Mar. 31, 2022
Revenue from Contract with Customer [Abstract]
Revenue	Note 3. Revenue Contract Balances The timing of revenue recognition, billings, and cash collections results in trade and unbilled receivables, and deferred revenues on the consolidated balance sheets. The Company may offer longer or extended payments of more than one year for qualified customers in some circumstances. At times, revenue recognition occurs before the billing, resulting in an unbilled receivable, which represents a contract asset. The contract asset is a component of accounts receivable and other assets for the current and non-current portions, respectively. When the Company receives advances or deposits from customers before revenue is recognized, this results in a contract liability. It can take up to two and half years from the time of order to revenue recognition due to the Company’s long sales cycle. Changes in the contract assets and contract liabilities are as follows: March 31, June 30, (Dollars in thousands) Amount Amount Contract Assets: Unbilled accounts receivable – current (1) $ 8,204 $ 12,354 Interest receivable – current (2) 547 512 Long-term accounts receivable (3) 4,906 4,970 Interest receivable – non-current (3) 762 1,083 Contract Liabilities: Customer advances 24,363 24,937 Deferred revenue – current 76,732 81,660 Deferred revenue – non-current 24,550 23,685 (1) Included in accounts receivable on the Company’s consolidated balance sheet (2) Included in prepaid expenses and other current assets on the Company’s consolidated balance sheet (3) Included in other assets on the Company’s consolidated balance sheet During the quarter ended March 31, 2022, contract assets changed primarily due to changes in the timing of billings that occurred after revenues were recognized and changes in transactions with payment terms exceeding 12 months. Contract liabilities changed due to changes in the timing of recognition of revenue for system sales for which the warranty has not yet started and was deferred and due to changes in transaction price. During the three and nine months ended March 31, 2022, the Company recognized revenues of $ 12.5 million and $ 71.2 million, respectively, which were included in the deferred revenues balances at June 30, 2021. During the three and nine months ended March 31, 2021, the Company recognized revenues of $ 6.5 million and $ 23.7 million, respectively, which were included in the deferred revenues balances at June 30, 2020. Remaining Performance Obligations Remaining performance obligations represent deferred revenue from open contracts for which performance has already started and the transaction price from executed contracts for which performance has not yet started. Service contracts in general are considered month-to-month contracts. As of March 31, 2022 , total remaining performance obligations amounted to $ 1,121.8 million. Of this total amount, $ 70.1 million related to long-term warranty and service, such as non-cancellable post contract services and system warranty, which is expected to be recognized over the remaining service period and warranty period for systems that have been delivered, respectively. The following table represents the Company's remaining performance obligations related to long-term warranty and non-cancellable post warranty services as of March 31, 2022 and the estimated revenue expected to be recognized (the time bands reflect management’s best estimate of when the Company will transfer control to the customer and may change based on timing of shipment, readiness of customers’ facilities for installation, installation requirements, and availability of products). The Company has elected the practical expedient to not disclose the unsatisfied performance obligations of contracts with an original expected duration of one year or less. Fiscal years of revenue recognition (Dollars in thousands) 2022 2023 2024 Thereafter Long-term warranty and service $ 8,596 $ 28,337 $ 18,202 $ 14,993 For the remaining $ 1,051.7 million of performance obligations, the Company estimates 19 % to 23 % will be recognized in the next 12 months, and the remaining portion will be recognized thereafter. The Company’s historical experience indicates that some of its customers will cancel or renegotiate contracts as economic conditions change or when product offerings change during the long sales cycle. The Company anticipates a portion of its open contracts may never result in revenue recognition primarily due to the long sales cycle and factors outside of its control including changes in customers' needs or financial condition, changes in government or health insurance reimbursement policies or changes to regulatory requirements. Based on historical experience, approximately 29 % of the Company’s $ 1,051.7 million remaining performance obligations may never result in revenue. Capitalized Contract Costs As of March 31, 2022 and June 30, 2021, the balance of capitalized costs to obtain a contract was $ 10.7 million and $ 8.9 million, respectively. The Company has classified the capitalized costs to obtain a contract as a component of prepaid expenses and other current assets and other assets with respect to the current and non-current portions of capitalized costs, respectively, on the consolidated balance sheets. The Company incurred impairment losses of $ 0.1 million and $ 0.4 million, respectively, in the three and nine month periods ended March 31, 2022 and $ 0.2 million and $ 0.5 million, respectively, in the three and nine month periods ended March 31, 2021, respectively. During the three and nine months period ended March 31, 2022, the Company recognized $ 1.0 million and $ 2.8 million, respectively in expense related to the amortization of the capitalized contract costs. During the three and nine months ended March 31, 2021, the Company recognized $ 0.8 million and $ 2.0 million, respectively, in expense related to the amortization of the capitalized contract costs.

Supplemental Financial Informat

Supplemental Financial Information	9 Months Ended
	Mar. 31, 2022
Supplemental Financial Information Disclosure [Abstract]
Supplemental Financial Information	Note 4. Supplemental Financial Information Balance Sheet Components Financing receivables A financing receivable is a contractual right to receive money, on demand or on fixed or determinable dates, that is recognized as an asset in the Company’s balance sheet. The Company’s financing receivables, consisting of its accounts receivable with contractual maturities of more than one year, totaled $ 2.8 million and $ 3.4 million at March 31, 2022 and June 30, 2021, respectively, and are included in Other Assets in the unaudited condensed consolidated balance sheet. The Company evaluates the credit quality of a customer at contract inception and monitors credit quality over the term of the underlying transactions. The Company performs a credit analysis for all new customers and reviews payment history, current order backlog, financial performance of the customers and other variables that augment or mitigate the inherent credit risk of a particular transaction. Such variables include the underlying value and liquidity of the collateral, the essential use of the equipment, the contract term and the inclusion of credit enhancements, such as guarantees, letters of credit or security deposits. The Company classifies accounts as high risk when it considers the financing receivable to be impaired or when management believes there is a significant near‑term risk of non‑payment. The Company performed an assessment of the allowance for credit losses related to its financing receivables. Based upon such assessment, the allowance for credit losses related to such financing receivables was $ 0.9 million for the periods ended March 31, 2022 and June 30, 2021. A summary of the Company’s financing receivables is presented as follows (in thousands): March 31, June 30, Financing receivable $ 6,162 $ 7,102 Allowance for credit loss ( 943 ) ( 943 ) Total, net $ 5,219 $ 6,159 Reported as: Current $ 2,458 $ 2,772 Non-current 2,761 3,387 Total, net $ 5,219 $ 6,159 The Company added and wrote off no amount from the allowance for credit losses during the nine months ended March 31, 2022. The Company added $ 0.2 million and wrote off $ 3.6 million from the allowance for credit losses in fiscal year 2021. Inventories Inventories consisted of the following (in thousands): March 31, June 30, Raw materials $ 56,804 $ 45,301 Work-in-process 17,642 22,014 Finished goods 63,073 58,614 Inventories $ 137,519 $ 125,929 Property and equipment, net Property and equipment, net consisted of the following (in thousands): March 31, June 30, Furniture and fixtures $ 1,783 $ 1,636 Computer and office equipment 8,677 8,972 Software 5,374 7,477 Leasehold improvements 26,674 26,102 Machinery and equipment 46,411 45,265 Construction in progress 2,043 1,055 90,962 90,507 Less: Accumulated depreciation ( 78,742 ) ( 78,175 ) Property and equipment, net $ 12,220 $ 12,332 Depreciation expense related to property and equipment for the three and nine months ended March 31, 2022 was $ 1.4 million and $ 4.1 million, respectively. Depreciation expense related to property and equipment for the three and nine months ended March 31, 2021 was $ 1.5 million and $ 4.7 million, respectively. Accumulated Other Comprehensive Income The changes in accumulated other comprehensive income are excluded from earnings and reported as a component of stockholders’ equity. The foreign currency translation adjustment results from those subsidiaries not using the U.S. Dollar as their functional currency since the majority of their economic activities are primarily denominated in their applicable local currency. Accordingly, all assets and liabilities related to these operations are translated to the U.S. Dollar at the current exchange rates at the end of each period. Revenues and expenses are translated at average exchange rates in effect during the period. The components of accumulated other comprehensive income in the equity section of the Company’s condensed consolidated balance sheet are as follows (in thousands): March 31, June 30, Cumulative foreign currency translation adjustment $ 1,567 $ 2,457 Defined benefit pension obligation ( 364 ) ( 364 ) Accumulated other comprehensive income $ 1,203 $ 2,093

Leases

Leases	9 Months Ended
	Mar. 31, 2022
Leases [Abstract]
Leases	Note 5. Leases The Company has operating leases for corporate offices and warehouse facilities worldwide. Additionally, the Company leases cars, copy machines and laptops that are considered operating leases. Some of the Company’s leases are non-cancellable operating lease agreements with various expiration dates through September 2026. Certain lease agreements include options to renew or terminate the lease, which are not reasonably certain to be exercised and therefore are not factored into the determination of lease payments. Operating lease costs for the three and nine months ended March 31, 2022 were $ 2.3 million and $ 7.0 million, not including short-term operating lease costs of $ 0.1 million and $ 0.3 million, respectively. Operating lease costs for the three and nine months ended March 31, 2021 were $ 2.2 million and $ 6.8 million, not including short-term operating lease costs of $ 0.1 million and $ 0.3 million, respectively. For the three and nine months ended March 31, 2022 , cash paid for amounts included in the measurement of operating lease liabilities was approximately $ 2.4 million and $ 7.3 million, respectively. Operating lease liabilities arising from operating right-of-use assets, which totaled $ 0.5 million and $ 1.5 million for the three and nine months ended March 31, 2022, respectively. For the three and nine months ended March 31, 2021, cash paid for amounts included in the measurement of operating lease liabilities was approximately $ 2.4 million and $ 7.2 million, respectively. Operating lease liabilities arising from obtaining operating right-of-use assets totaled $ 0.2 million and $ 0.8 million for the three and nine months ended March 31, 2021, respectively. Operating lease right-of-use assets and operating lease obligations are represented in the table below (in thousands): March 31, June 30, Beginning balance operating lease right-of-use asset $ 22,522 $ 28,647 Lease asset added 1,486 1,069 Amortization for the year ( 6,157 ) ( 7,194 ) Ending balance operating lease right-of-use asset $ 17,851 $ 22,522 Beginning balance operating lease obligation $ 25,610 $ 32,397 Lease liability added 1,486 1,069 Repayment and interest accretion ( 6,816 ) ( 7,856 ) Ending balance operating lease obligation $ 20,280 $ 25,610 Current portion of operating lease obligation $ 8,351 $ 8,169 Noncurrent portion of operating lease obligation $ 11,929 $ 17,441 Maturities of operating lease liabilities as of March 31, 2022 are presented in the table below (in thousands): Year Ending June 30, Amount 2022 (remaining 3 months) $ 2,454 2023 9,321 2024 6,437 2025 3,445 2026 91 Thereafter — Total operating lease payments 21,748 Less: imputed interest ( 1,466 ) Present value of operating lease liabilities $ 20,282 Weighted average remaining lease term (in years) 2.50 Weighted average discount rate 5.67 %

Goodwill and Intangible Assets

Goodwill and Intangible Assets	9 Months Ended
	Mar. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	Note 6. Goodwill and Intangible Assets Goodwill Activity related to goodwill consisted of the following (in thousands): March 31, June 30, Balance at the beginning of the period $ 57,960 $ 57,717 Currency translation 40 243 Balance at the end of the period $ 58,000 $ 57,960 In the second quarter of fiscal 2022, the Company performed its annual goodwill impairment test and determined that there was no impairment to goodwill. The Company did not identify any triggering events that would indicate potential impairment of its definite-lived intangible and long-lived assets as of March 31, 2022. Intangible Assets The Company’s carrying amount of acquired intangible assets, net, is as follows (in thousands): March 31, 2022 June 30, 2021 Useful Gross Accumulated Net Gross Accumulated Net (in years) Patent license 2 - 7 $ 1,170 $ ( 884 ) $ 286 $ 1,170 $ ( 735 ) $ 435 During fiscal 2017, the Company purchased a patent license with a useful life of seven years . During the quarter ending March 31, 2020, the Company purchased a patent license for $ 170 thousand with a useful life of two years . The Company did not identify any triggering events that would indicate potential impairment of its definite-lived intangible and long-lived assets as of March 31, 2022 and June 30, 2021. Amortization expense related to intangible assets for the three and nine months ended March 31, 2022, was $ 0.04 million and $ 0.2 million, respectively. Amortization expense related to intangible assets for the three and nine months ended March 31, 2021 was $ 0.06 million and $ 0.2 million, respectively. The estimated future amortization expense of acquired intangible assets as of March 31, 2022 is as follows (in thousands): Year Ending June 30, Amount 2022 (remaining 3 months) $ 36 2023 143 2024 107 2025 — $ 286

Derivative Financial Instrument

Derivative Financial Instruments	9 Months Ended
	Mar. 31, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Financial Instruments	Note 7. Derivative Financial Instruments The Company utilizes foreign currency forward contracts with reputable financial institutions to manage its exposure to fluctuations in foreign currency exchange rates on certain intercompany balances and foreign currency denominated cash, customer receivables and liabilities. The Company does not use derivative financial instruments for speculative or trading purposes. These forward contracts are not designated as hedging instruments for accounting purposes. Principal hedged currencies include the Euro, Japanese Yen, Swiss Franc, and U.S. Dollar. The periods of these forward contracts range up to approximately three months and the notional amounts are intended to be consistent with changes in the underlying exposures. The Company intends to exchange foreign currencies for U.S. Dollars at maturity. As of March 31, 2022 and June 30, 2021, the Company had the following outstanding forward currency exchange contracts (in notional amount): March 31, As of June 30, (In thousands and U.S. dollars) 2022 2021 Canadian Dollar $ 2,171 $ 527 Swiss Franc 30,521 8,891 Chinese Yuan 687 1,927 Euro 3,862 19,037 British Pound 863 3,191 Indian Rupee 3,328 7,825 Japanese Yen 8,126 12,803 $ 49,558 $ 54,201 The Company entered into the foreign currency forward contracts on March 31, 2022 and June 30, 2021, respectively, and therefore, there was no amount recorded on the balance sheet. The following table provides information about gain (loss) associated with the Company’s derivative financial instruments (in thousands): Three Months Ended Nine Months Ended 2022 2021 2022 2021 Foreign currency exchange gain (loss) on forward contracts $ ( 234 ) $ 108 $ ( 860 ) $ ( 1,055 ) Foreign currency transactions gain (loss) ( 172 ) ( 134 ) ( 947 ) 490

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Mar. 31, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurements	Note 8. Fair Value Measurements Fair value is an exit price representing the amount that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The fair value hierarchy contains three levels of inputs that may be used to measure fair value, as follows: Level 1— Unadjusted quoted prices that are available in active markets for the identical assets or liabilities at the measurement date. Level 2— Other observable inputs available at the measurement date, other than quoted prices included in Level 1, either directly or indirectly, including: • Quoted prices for similar assets or liabilities in active markets; • Quoted prices for identical or similar assets in non-active markets; • Inputs other than quoted prices that are observable for the asset or liability; and • Inputs that are derived principally from or corroborated by other observable market data. Level 3— Unobservable inputs that cannot be corroborated by observable market data and require the use of significant management judgment. These values are generally determined using pricing models for which the assumptions utilize management’s estimates of market participant assumptions. Assets and Liabilities That Are Measured at Fair Value on a Nonrecurring Basis As of March 31, 2022, the Company had open currency forward contracts to purchase or sell foreign currencies with a stated, or notional, value of approximately $ 49.6 million. The fair value of the underlying currency based upon the March 31, 2022 exchange rate was approximately $ 49.6 million, which it considers to be a Level 1 fair value measurement. As of June 30, 2021, the Company had open currency forward contracts to purchase or sell foreign currencies with a stated, or notional, value of approximately $ 54.2 million. The fair value of the underlying currency based upon the June 30, 2021 exchange rate was approximately $ 54.2 million, which it considers to be a Level 1 fair value measurement. The Company’s debt is measured on a non-recurring basis using Level 2 inputs based upon observable inputs of the Company’s underlying stock price and the time value of the conversion option since an observable quoted price of the 3.75 % Convertible Notes (as defined below) is not readily available. The Revolving Credit Facility (as defined below) and the Term Loan (as defined below) are valued at market interest rates, which the Company considers to be a Level 2 fair value measurement. The Company believes that the carrying value of these financial instruments approximate its estimated fair value based on the effective interest rate compared to the current market rate available to the Company and analyzed at quarter-end. The following table summarizes the carrying value and estimated fair value of the Term Loan, the Revolving Credit Facility, the 3.75 % Convertible Notes due 2022 and the 3.75% Convertible Notes due 2026 (in thousands): March 31, June 30, Carrying Fair Carrying Fair 3.75 % Convertible Notes Due 2022 $ 2,858 $ 2,814 $ 2,712 $ 3,164 3.75 % Convertible Notes Due 2026 97,481 98,312 72,388 108,163 Term Loan Facility 75,908 75,908 78,697 78,697 Revolving Credit Facility 5,000 5,000 20,000 20,000 Total $ 181,247 $ 182,034 $ 173,797 $ 210,024

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Mar. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 9. Commitments and Contingencies Litigation From time to time, the Company is involved in legal proceedings arising in the ordinary course of its business. The Company records a provision for a loss when it believes that it is both probable that a loss has been incurred and the amount can be reasonably estimated. To the extent there is a reasonable possibility that a loss exceeding amounts already recognized may be incurred and the amount of such additional loss would be material, we will either disclose the estimated additional loss or state that such an estimate cannot be made. Currently, management believes the Company does not have any probable and reasonably estimable material losses related to any current legal proceedings and claims. Although occasional adverse decisions or settlements may occur, management does not believe that an adverse determination with respect to any of these claims would individually or in the aggregate materially and adversely affect the Company’s financial condition or operating results. Litigation is inherently unpredictable and is subject to significant uncertainties, some of which are beyond the Company’s control. Should any of these estimates and assumptions change or prove to have been incorrect, the Company could incur significant charges related to legal matters that could have a material impact on its results of operations, financial position and cash flows. Indemnities Under the terms of the Company’s software license agreements with its customers, the Company agrees that in the event the software sold infringes upon any patent, copyright, trademark, or any other proprietary right of a third‑party, it will indemnify its customer licensees against any loss, expense, or liability from any damages that may be awarded against its customer. The Company includes this infringement indemnification in all of its software license agreements and selected managed services arrangements. In the event the customer cannot use the software or service due to infringement and the Company cannot obtain the right to use, replace or modify the license or service in a commercially feasible manner so that it no longer infringes, then the Company may terminate the license and provide the customer a refund of the fees paid by the customer for the infringing license or service. The Company has not recorded any liability associated with this indemnification, as it is not aware of any pending or threatened actions that represent probable losses as of March 31, 2022. The Company enters into standard indemnification agreements with its landlords and all superior mortgagees and their respective directors, officers’ agents, and employees in the ordinary course of business. Pursuant to these agreements, the Company will indemnify, hold harmless, and agree to reimburse the indemnified party for losses suffered or incurred by the indemnified party, generally the landlords, in connection with any loss, accident, injury, or damage by any third‑party with respect to the leased facilities. The term of these indemnification agreements is from the commencement of the lease agreements until termination of the lease agreements. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is unlimited; however, historically, the Company has not incurred claims or costs to defend lawsuits or settle claims related to these indemnification agreements. The Company has not recorded any liability associated with its indemnification agreements as it is not aware of any pending or threatened actions that represent probable losses as of March 31, 2022. Guarantees As of March 31, 2022 and June 30, 2021, the Company had various bank guarantees totaling approximately $ 0.9 million and $ 1.2 million, respectively, related to bidding processes with customers. Royalty Agreement The Company recorded royalty costs of $ 0.3 million and $ 1.2 million for the three and nine months ended March 31, 2022, respectively, and $ 0.4 million and $ 1.3 million for the three and nine months ended March 31, 2021, respectively, which were recorded in cost of revenue or deferred cost of revenue. The Company had approximately $ 2.2 million and $ 2.3 million accrued liabilities at March 31, 2022 and June 30, 2021, respectively, related to royalty agreements.

Debt

Debt	9 Months Ended
	Mar. 31, 2022
Debt Disclosure [Abstract]
Debt	Note 10. Debt 3.75% Convertible Senior Notes due July 2022 In August 2017, the Company issued $ 85.0 million aggregate principal amount of its 3.75 % Convertible Senior Notes due 2022 (the “ 3.75 % Convertible Notes due 2022”) under an indenture between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee. $ 53.0 million aggregate principal amount of the 3.75 % Convertible Notes due 2022 were issued to certain holders of the Company’s then outstanding 3.50 % Convertible Notes due 2018 and 3.50 % Series A Convertible Notes due 2018 (together, the “Prior Existing Notes”) in exchange for approximately $ 47.0 million aggregate principal amount of the Prior Existing Notes and $ 32.0 million aggregate principal amount of the 3.75 % Convertible Notes due 2022 were issued to certain other qualified new investors for cash. The net proceeds of the cash issuance were used to repurchase approximately $ 28.0 million of Prior Existing Notes. Holders of the 3.75 % Convertible Notes due 2022 may convert their notes at any time on or after April 15, 2022 until the close of the business day immediately preceding the maturity date. Prior to April 15, 2022, holders of the 3.75 % Convertible Notes due 2022 may convert their notes only under certain circumstances. Upon conversion, the Company will have the right to pay cash, or deliver shares of common stock of the Company or a combination thereof, at the Company’s election. The initial conversion rate is 174.8252 shares of the Company’s common stock per $ 1,000 principal amount (which represents an initial conversion price of approximately $ 5.72 per share of the Company’s common stock). The conversion rate, and thus the conversion price, is subject to adjustment as further described below. Holders of the 3.75 % Convertible Notes due 2022 who convert their notes in connection with a “make-whole fundamental change,” as defined in the indenture, may be entitled to a make-whole premium in the form of an increase in the conversion rate. Additionally, in the event of a “fundamental change,” as defined in the indenture, holders of the 3.75 % Convertible Notes due 2022 may require the Company to purchase all or a portion of their note at a fundamental change repurchase price equal to 100 % of the principal amount of the 3.75 % Convertible Notes due 2022, plus accrued and unpaid interest, if any, to, but not including, the fundamental change repurchase date. In May 2021, the Company exchanged approximately $ 82.1 million aggregate principal amount of 3.75 % Convertible Notes due 2022 for approximately $ 97.1 million aggregate principal amount of 3.75 % Convertible Notes due 2026 (as defined below). As of June 30, 2021, $ 2.9 million aggregate principal amount of 3.75 % Convertible Notes due 2022 remained outstanding. The exchange was treated as extinguishment of debt. The Company recorded a loss on the extinguishment of debt of $ 4.3 million, primarily comprised of the write-off of deferred costs associated with the 3.75 % Convertible Notes due 2022 and the extinguishment of the equity component of $ 14.5 million recognized as reduction to additional paid in capital. The $ 14.5 million, which is the difference between the settlement consideration paid of $ 96.0 million and the fair value of the liability component of $ 81.5 million, represents the estimated fair value of the liability component based on the expected future cash flows associated with the aggregate principal amount of $ 82.1 million in 3.75 % Convertible Notes due 2022. As of March 31, 2022, $ 2.9 million aggregate principal amount of 3.75 % Convertible Notes due 2022 remained outstanding. 3.75% Convertible Senior Notes due July 2026 In May 2021, the Company issued $ 100.0 million aggregate principal amount of its 3.75 % Convertible Senior Notes due 2026 (the “ 3.75 % Convertible Notes due 2026”) under an indenture between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee. $ 97.1 million aggregate principal amount of the 3.75 % Convertible Notes due 2026 were issued to certain holders of the Company’s outstanding 3.75 % Convertible Notes due 2022 in exchange for approximately $ 82.1 million aggregate principal amount of 3.75 % Convertible Notes due 2022 and $ 2.9 million of 3.75 % Convertible Notes due 2026 were issued to certain other qualified new investors for cash (such transactions the “Exchange and Subscription Transactions”). Holders of the 3.75 % Convertible Notes due 2026 may convert their notes at any time on or after March 6, 2026 until the close of the business day immediately preceding the maturity date. Prior to June 6, 2026, holders of the 3.75 % Convertible Notes due 2026 may convert their notes only under certain circumstances. Upon conversion, the Company will have the right to pay cash, or deliver shares of common stock of the Company or a combination thereof, at the Company’s election. The initial conversion rate is 170.5611 shares of the Company’s common stock per $ 1,000 principal amount (which represents an initial conversion price of approximately $ 5.86 per share of the Company’s common stock). The conversion rate, and thus the conversion price, is subject to adjustment as further described below. Holders of the 3.75 % Convertible Notes due 2026 who convert their notes in connection with a “make-whole fundamental change,” as defined in the indenture, may be entitled to a make-whole premium in the form of an increase in the conversion rate. Additionally, in the event of a “fundamental change,” as defined in the indenture, holders of the 3.75 % Convertible Notes due 2026 may require the Company to purchase all or a portion of their note at a fundamental change repurchase price equal to 100 % of the principal amount of the 3.75 % Convertible Notes due 2026, plus accrued and unpaid interest, if any, to, but not including, the fundamental change repurchase date. As of June 30, 2021 and March 31, 2022, $ 100.0 million aggregate principal amount of 3.75 % Convertible Notes due 2026 was outstanding. The aggregate principal amount of $ 100.0 million, including $ 2.9 million which were issued to new qualified investors for cash in the 3.75 % Convertible Notes due 2026, was allocated between liability component of $ 74.1 million and equity component of $ 25.9 million recognized as addition paid in capital, reduced by $ 0.7 million of 3.75 % Convertible Notes due 2026 issuance cost allocated to additional paid in capital. Upon adoption of ASU No. 2020-06 on July 1, 2021, the Company recorded an increase to Accumulated deficit of $ 0.8 million, a decrease to Additional paid-in capital of $ 25.6 million, an increase to Debt, current of $ 24.8 million. There was no impact to diluted loss per share as the inclusion of potential shares of common stock related to the 3.75 % Convertible Notes due 2026 would have been anti-dilutive. The Company reversed the separation of the debt and equity components and accounted for the 3.75 % Convertible Notes due 2026 wholly as debt. The Company also reversed the amortization of the debt discount, with a cumulative adjustment to retained earnings on the adoption date. Debt issuance costs related to the 3.75 % Convertible Notes due 2022 and the 3.75 % Convertible Notes due 2026 were comprised of discounts, issuance costs and third party costs of $ 25.6 million. Prior to the adoption of ASU No. 2020-06, the Company allocated the total amount incurred to the liability and equity components of the 3.75 % Convertible Notes due 2022 and the 3.75 % Convertible Notes due 2026 based on their relative values. Issuance costs attributable to the liability component were $ 0.8 million and were amortized to interest expense using the effective interest method. Issuance costs attributable to the equity component were netted with the equity component in stockholders’ equity. Upon adoption of ASU No. 2020-06 on July 1, 2021, the Company reversed the allocation of the issuance costs to the equity component and accounted for the entire amount as debt issuance cost that will be amortized as interest expense for each of the respective terms of the 3.75% Convertible Notes due 2022 and the 3.75% Convertible Notes due 2026, respectively, with a cumulative adjustment to retained earnings on the adoption date. As of March 31, 2022, the if-converted value of the 3.75% Convertible Notes due 2022 and the 3.75% Convertible Notes due 2026 did not exceed the outstanding principal amount. Credit Facilities On May 6, 2021, the Company entered into a senior secured credit agreement (the “Credit Agreement”) with Silicon Valley Bank, individually as a lender and agent (“Agent”), and the other lenders from time to time parties thereto (together with Silicon Valley Bank as a lender, the “Lenders”), which provides for a five-year $ 80 million term loan (the “Term Loan Facility”) and a $ 40 million revolving credit facility (the “Revolving Credit Facility” and, together with the Term Loan Facility, the “Credit Facilities”). The initial borrowings under the Credit Agreement, including $ 25 million under the Revolving Credit Facility, were funded on May 14, 2021. Interest on the borrowings under the Credit Facilities is payable in arrears on the applicable interest payment date at an annual interest rate of reserve-adjusted, 90-day LIBOR (subject to a 0.50 % floor) plus, initially, 3.00 % and after the Agent receives copies of the consolidated financial statements of the Company for the fiscal quarter ending June 30, 2021: 3.25 % if the Consolidated Senior Net Leverage Ratio (as defined in the Credit Agreement) is greater than or equal to 3.00:1.00; 3.00 % if the Consolidated Senior Net Leverage Ratio is greater than or equal to 2.00:1.00 but less than 3.00:1.00; 2.75 % if the Consolidated Senior Net Leverage Ratio is greater than or equal to 1.00:1.00 but less than 2.00:1.00; and 2.50 % if the Consolidated Senior Net Leverage Ratio is less than 1.00:1.00. The Credit Agreement requires the Company to pay the Lenders an unused commitment fee equal to, initially, 0.35 % per annum of the average unused portion of the Revolving Credit Facility and after the Agent receives copies of the consolidated financial statements of the Company for the fiscal quarter ending June 30, 2021: 0.40 % per annum of the average unused portion of the Revolving Credit Facility if the Consolidated Senior Net Leverage Ratio is greater than or equal to 3.00:1.00; 0.35 % per annum of the average unused portion of the Revolving Credit Facility if the Consolidated Senior Net Leverage Ratio is greater than or equal to 2.00:1.00 but less than 3.00:1.00; 0.30 % per annum of the average unused portion of the Revolving Credit Facility if the Consolidated Senior Net Leverage Ratio is greater than or equal to 1.00:1.00 but less than 2.00:1.00; and 0.25 % per annum of the average unused portion of the Revolving Credit Facility if the Consolidated Senior Net Leverage Ratio is less than 1.00:1.00. If all or a portion of the loans under the Term Loan Facility are prepaid, then the Company will be required to pay a fee equal to 1 % of the of the aggregate amount of the loans so prepaid, subject to certain exceptions. The Credit Agreement contains restrictions and covenants applicable to the Company and its subsidiaries. Among other requirements, the Company may not permit the Fixed Charge Coverage Ratio (as defined in the Credit Agreement) to be less than a certain specified ratio for each fiscal quarter during the term of the Credit Agreement or the Consolidated Senior Net Leverage Ratio to be greater than a certain specified ratio for each fiscal quarter during the term of the Credit Agreement. The Credit Agreement also contains customary covenants that limit, among other things, the ability of the Company and its subsidiaries to (i) incur indebtedness, (ii) incur liens on their property, (iii) pay dividends or make other distributions, (iv) sell their assets, (v) make certain loans or investments, (vi) merge or consolidate, (vii) voluntarily repay or prepay certain indebtedness and (viii) enter into transactions with affiliates, in each case subject to certain exceptions. The Credit Agreement contains customary representations and warranties and events of default. As of June 30, 2021, $ 20.0 million of aggregate principal amount was outstanding under the Revolving Credit Facility, $ 80 million aggregate principal amount was outstanding under the Term Loan Facility and $ 1.3 million of associated unamortized debt costs. As of March 31, 2022, $ 5.0 million of aggregate principal amount was outstanding under the Revolving Credit Facility, $ 77.0 million aggregate principal amount was outstanding under the Term Loan Facility and $ 1.1 million of associated unamortized debt costs. The following table presents the carrying value of the Notes (as defined below), the Revolving Credit Facility and the Term Loan (in thousands): As of March 31, 2022 Revolving 3.75% 3.75% Term Loan Total Principal amount of the Notes $ 5,000 $ 2,865 $ 100,000 $ 77,000 $ 184,865 Unamortized debt costs — ( 7 ) ( 2,519 ) ( 1,092 ) ( 3,618 ) Net carrying amount $ 5,000 $ 2,858 $ 97,481 $ 75,908 $ 181,247 Reported as: Short-term debt $ 8,051 Long-term debt 173,196 Total debt $ 181,247 As of June 30, 2021 Revolving 3.75% 3.75% Term Loan Total Carrying amount of equity conversion component $ — $ 134 $ 25,944 $ — $ 26,078 Principal amount of the Notes $ 20,000 $ 2,865 $ 100,000 $ 80,000 $ 202,865 Unamortized debt costs — ( 34 ) ( 2,175 ) ( 1,303 ) ( 3,512 ) Unamortized debt discount — ( 119 ) ( 25,437 ) — ( 25,556 ) Net carrying amount $ 20,000 $ 2,712 $ 72,388 $ 78,697 $ 173,797 Reported as: Short-term debt $ 3,790 Long-term debt 170,007 Total debt $ 173,797 A summary of interest expense on the Notes and Credit Facilities is as follows (in thousands): Three Months Ended Nine Months Ended 2022 2021 2022 2021 Interest expense related to contractual interest coupon $ 1,748 $ 2,678 $ 5,466 $ 8,259 Interest expense related to amortization of debt discount — 1,266 — 3,757 Interest expense related to amortization of debt issuance 215 370 594 1,086 $ 1,963 $ 4,314 $ 6,060 $ 13,102

Share-Based Compensation

Share-Based Compensation	9 Months Ended
	Mar. 31, 2022
Share-based Payment Arrangement [Abstract]
Share-Based Compensation	Note 11. Share-Based Compensation The following table presents details of share-based compensation expenses by functional line item noted within the Company's operating expenses (in thousands): Three Months Ended Nine Months Ended 2022 2021 2022 2021 Cost of revenue $ 388 $ 345 $ 1,192 $ 949 Research and development 317 324 1,037 1,023 Selling and marketing 598 379 1,614 1,060 General and administrative 1,397 1,441 4,068 4,065 $ 2,700 $ 2,489 $ 7,911 $ 7,097

Net Income (Loss) Per Common Sh

Net Income (Loss) Per Common Share	9 Months Ended
	Mar. 31, 2022
Earnings Per Share [Abstract]
Net Income (Loss) Per Common Share	Note 12. Net Income (loss) Per Common Share The Company reports both basic and diluted income (loss) per share, which is based on the weighted average number of common shares outstanding during the period. A reconciliation of the numerator and denominator used in the calculation of basic and diluted net income (loss) per common share follows (in thousands): Three Months Ended Nine Months Ended 2022 2021 2022 2021 Numerator: Net income (loss) $ ( 1,046 ) $ ( 390 ) $ ( 1,895 ) $ 4,781 Denominator: Weighted average shares outstanding - basic 92,761 93,123 91,780 92,106 Dilutive effect of potential common shares — — — 1,316 Weighted average shares outstanding - diluted 92,761 93,123 91,780 93,422 Basic net income (loss) per share $ ( 0.01 ) $ ( 0.00 ) $ ( 0.02 ) $ 0.05 Diluted net income (loss) per share $ ( 0.01 ) $ ( 0.00 ) $ ( 0.02 ) $ 0.05 The potentially dilutive shares of the Company’s common stock resulting from the assumed exercise of outstanding stock options, the vesting of Restricted Stock Units (RSU), Market Stock Units (MSU) and Performance Stock Units (PSU), and the purchase of shares under the Employee Stock Purchase Program (ESPP), as determined under the treasury stock method, are excluded from the computation of diluted net income (loss) per share when their effect would have been anti‑dilutive. Additionally, the outstanding 3.75 % Convertible Notes due July 2022 (the “3.75% Convertible Notes due 2022”) and the 3.75 % Convertible Notes due June 2026 (the “3.75% Convertible Notes due 2026” and together with the 3.75% Convertible Notes due 2022, the “Notes”) are included in the calculation of diluted net income per share only if their inclusion is dilutive for periods during which the notes were outstanding. The following table sets forth all potentially dilutive securities excluded from the computation in the table above because their effect would have been anti-dilutive (in thousands): As of March 31, 2022 2021 Stock options 6,317 6,742 RSUs, PSUs and MSUs 4,422 3,076 10,739 9,818 3.75% Convertible Notes—Diluted Share Impact Due to the optional cash settlement feature and management’s intent to settle the principal amount thereof in cash, the shares of common stock issuable upon conversion of the outstanding principal amount of the 3.75 % Convertible Notes due 2022 and 3.75 % Convertible Notes due 2026 outstanding as of March 31, 2022, totaling approximately 0.5 million shares and 17.1 million shares of the Company’s common stock, respectively, as of March 31, 2022, the effect of adding the shares were antidilutive and were not included in the basic and diluted net income (loss) per common share table above. The shares of common stock issuable upon conversion of the outstanding principal amount of the 3.75 % Convertible Notes due 2022 outstanding as of March 31, 2021 totaled approximately 14.9 million shares of the Company’s common stock and the effect of adding the shares were antidilutive and were not included in the basic and diluted net income (loss) per common share table above.

Segment Information

Segment Information	9 Months Ended
	Mar. 31, 2022
Segment Reporting [Abstract]
Segment Information	Note 13. Segment Information The Company has one operating and reporting segment (oncology systems group), which develops, manufactures and markets proprietary medical devices used in radiation therapy for the treatment of cancer patients. The Company’s Chief Executive Officer, its Chief Operating Decision Maker, reviews financial information presented on a consolidated basis for purposes of making operating decisions and assessing financial performance. The Company does not assess the performance of its individual product lines on measures of profit or loss, or asset-based metrics. Therefore, the information below is presented only for revenues and long-lived tangible assets by geographic area. Disaggregation of Revenues The Company disaggregates its revenues from contracts by geographic region, as the Company believes this best depicts how the nature, amount, timing and uncertainty of revenues and cash flows are affected by economic factors. Additionally, the Company typically recognizes revenue at a point in time for product revenue and recognizes revenue over time for service revenue. Revenues attributed to a country or region is based on the shipping addresses of the Company’s customers. The following summarizes revenue by geographic region (in thousands): Three Months Ended Nine Months Ended 2022 2021 2022 2021 Americas $ 25,410 $ 25,062 $ 100,362 $ 78,418 Europe, Middle East, India and Africa 29,550 30,826 93,581 87,424 Asia Pacific, excluding Japan and China 8,871 3,658 22,690 17,239 Japan 11,751 13,869 33,512 41,386 China 20,587 29,147 69,741 60,886 Total $ 96,169 $ 102,562 $ 319,886 $ 285,353 Disaggregation of Long-Lived Assets Information regarding geographic areas in which the Company has long-lived tangible assets is as follows (in thousands): March 31, June 30, 2022 2021 Americas $ 10,468 $ 10,588 Europe, Middle East, India and Africa 269 265 Asia Pacific, excluding Japan and China 325 170 Japan 376 701 China 782 608 Total $ 12,220 $ 12,332

Joint Venture

Joint Venture	9 Months Ended
	Mar. 31, 2022
Equity Method Investments and Joint Ventures [Abstract]
Joint Venture	Note 14. Joint Venture In January 2019, the Company’s wholly-owned subsidiary, Accuray Asia Limited (“Accuray Asia”), entered into an agreement with CNNC High Energy Equipment (Tianjin) Co., Ltd. (the “CIRC Subsidiary”), a wholly-owned subsidiary of China Isotope & Radiation Corporation, to form a joint venture, CNNC Accuray (Tianjin) Medical Technology Co. Ltd. (the “JV”), to manufacture and sell radiation oncology systems in China. In exchange for a 49 % equity interest in the JV, the Company, through Accuray Asia, made in-kind capital contributions of two full radiation oncology systems in the quarter ended December 31, 2019 and one system upgrade in the quarter ended September 30, 2020, all of which was not to be sold and only be used for training purposes by the JV. The investments are reported as an Investment in joint venture on the Company’s consolidated balance sheets. The Company applies the equity method of accounting to its ownership interest in the JV as the Company has the ability to exercise significant influence over the JV but lacks controlling financial interest and is not the primary beneficiary. The Company recognizes revenue on sales to the JV in the current period, eliminating a portion of profit to the extent goods sold have not been sold through by the JV to an end customer at the end of such reporting period. The Company deferred $ 5.7 million and $ 2.1 million of intra-entity profit margin as of March 31, 2022 and June 30, 2021, respectively. During the three months ended March 31, 2022, the Company recognized $ 0.3 million of previously deferred intra-entity profit margin from sales and recorded intra-entity profit margin deferral of $ 2.9 million from sales executed during the period. During the nine months ended March 31, 2022, the Company recognized $ 1.5 million of previously deferred intra-entity profit margin from sales and recorded intra-entity profit margin deferral of $ 5.0 million from sales executed during the period. During the three months ended March 31, 2021, the Company recognized $ 0.4 million of previously deferred intra-entity profit margin from sales and recorded intra-entity profit margin deferral of $ 0.8 million from sales executed during the period. During the nine months ended March 31, 2021, the Company recognized $ 1.9 million of previously deferred intra-entity profit margin from sales and recorded intra-entity profit margin deferral of $ 1.7 million from system sales executed during the period. The Company’s consolidated accumulated deficit includes $ 1.5 million of accumulated gains related to the Company’s equity method investment. As of March 31, 2022, the Company had carrying value of $ 14.3 million in the JV and owned a 49 % interest in the entity. The Company’s proportional share of the underlying equity in net assets of the JV was approximately $ 15.2 million. Under the equity method of accounting, the carrying value of the investment is adjusted for the Company's proportional share of the investee's currency translation adjustment of $ 1.1 million. The difference between the carrying value of the equity investment and the Company’s proportional share of the underlying equity in net assets of the JV of $ 1.0 million, adding back $ 5.7 million of eliminated intra-entity profit, constitutes equity method goodwill of $ 4.7 million at March 31, 2022 that is subject to impairment analysis. No impairment was identified as of March 31, 2022. Summarized financial information of the JV is based one-quarter lag due to the timing of the availability of the JV’s financial records is as follows (in thousands): Nine Months Ended December 31, 2021 Nine Months Ended December 31, 2020 Statement of Operations Data: Revenue $ 44,819 $ 28,095 Gross Profit 13,590 8,864 Net income 1,511 2,089 Net income attributable to the Company 740 1,021 As of As of Summarized Balance Sheet Data: Assets Current assets $ 62,328 $ 19,895 Non current assets 22,136 22,446 $ 84,464 $ 42,341 Liabilities and Stockholders' Equity Current liabilities $ 52,085 $ 11,810 Non current liabilities 1,001 1,131 Stockholder's equity 31,378 29,400 $ 84,464 $ 42,341

Income Tax

Income Tax	9 Months Ended
	Mar. 31, 2022
Income Tax Disclosure [Abstract]
Income Tax	Note 15. Income Tax On a quarterly basis, the Company provides for income taxes based upon an estimated annual effective income tax rate. The Company recognized income tax expen se of $ 0.4 million and $ 1.3 million for t he three and nine months ended March 31, 2022, respectively, primarily related to foreign taxes. The Company recognized an income tax expense of $ 0.7 million and $ 1.4 million for the three and nine months ended March 31, 2021, respectively. Starting in fiscal year 2019, certain income earned by controlling foreign corporations (“CFCs”) must be included in the gross income of the CFC’s U.S. shareholder. The income required to be included in gross income is referred to as global intangible low tax income (“GILTI”) and is defined under IRC Section 951A as the excess of the shareholder’s net CFC tested income over the net deemed tangible income return. The GILTI inclusion amount is expected to be fully absorbed by net operating losses carryforward and is not expected to cause the Company to be in a U.S. taxable income position for fiscal year 2022. As of March 31, 2022, the Company’s gross unrecognized tax benefi ts was $ 18.8 million of which $ 18.6 mil lion would not affect income tax expense before consideration of any valuation allowance. The Company does not expect its unrecognized tax benefits to change significantly over the next 12 months . Interest and penalties accrued on unrecognized tax benefits is recorded as a component of income tax expense.

Subsequent Events

Subsequent Events	9 Months Ended
	Mar. 31, 2022
Subsequent Events [Abstract]
Subsequent Events	Note 16. Subsequent Events The Company has evaluated subsequent events through the filing of this Quarterly Report on Form 10-Q and determined that there have been no events that have occurred that would require adjustments to its disclosures in the consolidated financial statements.

The Company and its Significa_2

The Company and its Significant Accounting Policies (Policies)	9 Months Ended
	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant inter-company transactions and balances have been eliminated in consolidation. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (“GAAP”), pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Certain information and note disclosures have been condensed or omitted pursuant to such rules and regulations. The unaudited condensed consolidated financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for a fair presentation of the periods presented. The results for the three and nine months ended March 31, 2022 are not necessarily indicative of the results to be expected for the fiscal year ending June 30, 2022, or for any other future interim period or fiscal year. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and accompanying notes for the fiscal year ended June 30, 2021 included in the Company’s Annual Report on Form 10-K filed with the SEC on August 17, 2021.
Risks and Uncertainties	Risks and Uncertainties The Company is subject to risks and uncertainties as a result of a novel strain of coronavirus, severe acute respiratory syndrome coronavirus 2, or SARS-CoV-2, which causes coronavirus disease 2019 (“COVID-19”) and has resulted in a worldwide pandemic. The extent of the impact of the COVID-19 pandemic on the Company's business is highly uncertain and difficult to predict, as the effects of and response to the pandemic are rapidly evolving and new information is regularly coming to light, particularly as new COVID-19 variants emerge. The Company's customers are diverting resources to treat COVID-19 patients and deferring non-urgent and elective procedures. Some customers, which include hospitals, major academic medical centers, and other related entities, have incurred significant losses during the COVID-19 pandemic due to reduced patient volume. These impacts on the Company's customers may adversely affect their ability to meet their financial and other contractual obligations, including to the Company. Furthermore, global economic uncertainty, including labor shortages and disruptions in the global supply chain, related to the COVID-19 pandemic may result in an incremental adverse impact on revenue, net income (loss) and cash flow and may require significant additional expenditures or cost-cutting to mitigate such impacts. Policymakers around the globe have responded with fiscal policy actions to support the healthcare industry and economy as a whole. The magnitude and overall effectiveness of these actions remain uncertain. The Company’s financial results have also been affected by the COVID-19 pandemic in various ways. The COVID-19 pandemic is adversely impacting the pace at which the Company’s backlog converts to revenue. This is primarily the result of pandemic-related delays in the timing of deliveries and installations, which has adversely affected our revenue. The Company has experienced such delays in deliveries and installations since the third quarter of fiscal year 2020 and expects that such delays in will continue at least through the end of the calendar year of 2022, if not longer, which could have a negative impact on revenue. The Company has experienced disruptions in its sales cycle as well as delays in customer payments and service agreements. The Company has also received requests from a few customers to extend payment terms or temporarily suspend service and corresponding payment obligations. While the Company has only received a small number of requests thus far, there can be no guarantee that more customers will not ask for the same in the future. In addition, as the COVID-19 pandemic continues to impact the global supply chain, disruptions in parts of our supply chain have resulted in delays in the receipt of certain components for our products as well as increased pricing pressure for such parts. These ongoing supply chain challenges and heightened logistics costs have adversely affected the Company's gross margins and net income (loss), and the Company’s current expectations are that gross margins and net income (loss) will continue to be adversely affected by increased material costs and freight and logistic expenses through at least the remainder of the calendar year of 2022, if not longer. Furthermore, certain parts required for the manufacture and servicing of the Company's products, such as electronic components, are scarce and becoming increasingly difficult to source even at increased prices. If such parts become unavailable to the Company, it would not be able to manufacture or service our products, which would adversely impact revenue, gross margins, and net income (loss). As a result, the Company is carefully monitoring the pandemic and the potential length and depth of the resulting economic impact on our financial condition and results of operations. There remain uncertainties around the spread, severity and potential resurgence of COVID-19, the impact of new COVID-19 variants, vaccination deployment efforts, and how long the pandemic and associated health measures will last, the related financial impact cannot be reasonably estimated at this time, although the impacts are expected to continue and may significantly affect the Company’s business. The Company continues to critically review its liquidity and anticipated capital requirements in light of the significant uncertainty created by the COVID-19 pandemic. Based on the Company’s cash and cash equivalents balance, available debt facilities, current business plan and revenue prospects, the Company believes that it will have sufficient cash resources and anticipated cash flows to fund its operations for at least the next 12 months. However, the Company is unable to predict with certainty the impact of the COVID-19 pandemic, including its effect on global supply chain and logistics, will have on its ability to maintain compliance with the debt covenants contained in the credit agreement related to its Credit Facilities (as such terms are defined in Note 10 below), including financial covenants regarding the consolidated fixed charge coverage ratio and consolidated senior net leverage ratio. The Company was in compliance with such covenants at March 31, 2022. Failure to meet the covenant requirements in the future could cause the Company to be in default and the maturity of the related debt could be accelerated and become immediately payable. This may require the Company to obtain waivers or amendments to the credit agreement in order to maintain compliance and there can be no certainty that any such waiver or amendment will be available, or what the cost of such waiver or amendment, if obtained, would be. If the Company is unable to obtain necessary waivers or amendment and the debt under such credit facility is accelerated, the Company would be required to obtain replacement financing at prevailing market rates, which may not be favorable to the Company. There is no guarantee that the Company would be able to satisfy its obligations if any of its indebtedness is accelerated.
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and related disclosures at the date of the financial statements. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts of the COVID-19 pandemic. Key estimates and assumptions made by the Company relate to revenue recognition and the assessment of stand-alone selling price (“SSP”), assessment of recoverability of goodwill and intangible assets, valuation of our equity method investment in the JV, valuation of inventories, annual performance related bonuses, allowance for credit losses and loss contingencies. Actual results could differ materially from those estimates.
Significant Accounting Policies	Significant Accounting Policies Other than the policy adoption discussed below under Accounting Pronouncements Recently Adopted, there have been no changes in the Company’s significant accounting policies during the nine months ended March 31, 2022 compared to the significant accounting policies described in its Annual Report on Form 10-K for the fiscal year ended June 30, 2021 .

Recent Accounting Pronounceme_2

Recent Accounting Pronouncements (Policies)	9 Months Ended
	Mar. 31, 2022
Accounting Pronouncement Recently Adopted
Accounting Pronouncements	Accounting Pronouncement Recently Adopted In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying Accounting for Income Taxes (“ASU 2019-12”). The amendments in ASU 2019-12 are intended to simplify various aspects related to accounting for income taxes and reduce the cost of accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. The Company adopted ASU 2019-12 on July 1, 2021. The adoption of this standard did not have a material impact on its consolidated financial statements. In January 2020, the FASB issued ASU 2020-01 Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815) - Clarifying the Interactions between Topic 321, Topic 323, and Topic 815. This guidance addresses accounting for the transition into and out of the equity method and provides clarification of the interaction of rules for equity securities, the equity method of accounting, and forward contracts and purchase options on certain types of securities. This standard is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2020. The Company adopted ASU 2020-01 on July 1, 2021. The adoption of this standard did not have a material impact on its consolidated financial statements. In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) No. 2020-06 , Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40). Under ASU No. 2020-06, the embedded conversion features are no longer separated from the host contract for convertible instruments with conversion features that are not required to be accounted for as derivatives under Topic 815, or that do not result in substantial premiums accounted for as paid-in capital. Consequently, a convertible debt instrument will be accounted for as a single liability measured at its amortized cost, as long as no other features require bifurcation and recognition as derivatives. The new guidance also requires the if-converted method to be applied for all convertible instruments when calculating diluted earnings per share. The Company adopted this standard effective July 1, 2021, using a modified retrospective method, under which financial results reported in prior periods were not adjusted. The Company applied the provisions of this guidance to our 3.75 % convertible senior notes due June 2026 (“2026 Notes”). Upon adoption, the Company recorded an increase to Accumulated deficit of $ 0.8 million, a decrease to Additional paid-in capital of $ 25.6 million and an increase to Debt of $ 24.8 million. There was no impact to diluted loss per share as the inclusion of potential shares of common stock related to the 2026 Notes would have been anti-dilutive. For further information, see Note 10, Debt. In October 2020, the FASB issued ASU 2020-10, Codification Improvements - Disclosures. This ASU improves consistency by amending the codification to include all disclosure guidance in the appropriate disclosure sections and clarifies application of various provisions in the codification by amending and adding new headings, cross referencing to other guidance, and refining or correcting terminology. This ASU is effective for fiscal years beginning after December 15, 2020. This ASU will not affect the Company's results of operations, cash flows or financial position. The adoption of ASU No. 2020-10 by the Company effective July 1, 2021 did not have a material impact on the Company’s financial statements or disclosures.
Accounting Pronouncements Not Yet Effective
Accounting Pronouncements	Accounting Pronouncements Not Yet Effective In March 2020, the FASB issued an update (“ASU 2020-04”) establishing Accounting Standards Codification (“ASC”) Topic 848, Reference Rate Reform. ASU 2020-04 contains practical expedients for reference rate reform related activities that impact debt, leases, derivatives and other contracts. The guidance in ASU 2020-04 is optional and may be elected over time as reference rate reform activities occur. The Company’s Term Loan Facility and Revolving Credit Facility applies Eurodollar rate LIBOR to the variable component of the interest rate, if a Benchmark transition event, or an early opt-in election, as applicable occurred a transition to the use of the Secured Overnight Financing Rate ("SOFR") to replace such rate. The Company is currently evaluating the impact of the guidance and our options related to the practical expedients. In October 2021, the FASB issued ASU No. 2021-08, Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. The amendment addresses how to account for contract assets recognized under Topic 606 in a business combination. This standard is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2022. The Company is currently evaluating the impact ASU 2021-08 will have on its financial statements.

Revenue (Tables)

Revenue (Tables)	9 Months Ended
	Mar. 31, 2022
Revenue from Contract with Customer [Abstract]
Summary of Contract with Customer, Asset and Liability	Changes in the contract assets and contract liabilities are as follows: March 31, June 30, (Dollars in thousands) Amount Amount Contract Assets: Unbilled accounts receivable – current (1) $ 8,204 $ 12,354 Interest receivable – current (2) 547 512 Long-term accounts receivable (3) 4,906 4,970 Interest receivable – non-current (3) 762 1,083 Contract Liabilities: Customer advances 24,363 24,937 Deferred revenue – current 76,732 81,660 Deferred revenue – non-current 24,550 23,685 (1) Included in accounts receivable on the Company’s consolidated balance sheet (2) Included in prepaid expenses and other current assets on the Company’s consolidated balance sheet (3) Included in other assets on the Company’s consolidated balance sheet
Schedule of Remaining Performance Obligations related to Warranty	The following table represents the Company's remaining performance obligations related to long-term warranty and non-cancellable post warranty services as of March 31, 2022 and the estimated revenue expected to be recognized (the time bands reflect management’s best estimate of when the Company will transfer control to the customer and may change based on timing of shipment, readiness of customers’ facilities for installation, installation requirements, and availability of products). The Company has elected the practical expedient to not disclose the unsatisfied performance obligations of contracts with an original expected duration of one year or less. Fiscal years of revenue recognition (Dollars in thousands) 2022 2023 2024 Thereafter Long-term warranty and service $ 8,596 $ 28,337 $ 18,202 $ 14,993

Supplemental Financial Inform_2

Supplemental Financial Information (Tables)	9 Months Ended
	Mar. 31, 2022
Supplemental Financial Information Disclosure [Abstract]
Schedule of Financing Receivables	A summary of the Company’s financing receivables is presented as follows (in thousands): March 31, June 30, Financing receivable $ 6,162 $ 7,102 Allowance for credit loss ( 943 ) ( 943 ) Total, net $ 5,219 $ 6,159 Reported as: Current $ 2,458 $ 2,772 Non-current 2,761 3,387 Total, net $ 5,219 $ 6,159
Schedule of Inventories	Inventories consisted of the following (in thousands): March 31, June 30, Raw materials $ 56,804 $ 45,301 Work-in-process 17,642 22,014 Finished goods 63,073 58,614 Inventories $ 137,519 $ 125,929
Schedule of Property and Equipment, net	Property and equipment, net consisted of the following (in thousands): March 31, June 30, Furniture and fixtures $ 1,783 $ 1,636 Computer and office equipment 8,677 8,972 Software 5,374 7,477 Leasehold improvements 26,674 26,102 Machinery and equipment 46,411 45,265 Construction in progress 2,043 1,055 90,962 90,507 Less: Accumulated depreciation ( 78,742 ) ( 78,175 ) Property and equipment, net $ 12,220 $ 12,332
Schedule of Accumulated Other Comprehensive Income in the Equity Section	The components of accumulated other comprehensive income in the equity section of the Company’s condensed consolidated balance sheet are as follows (in thousands): March 31, June 30, Cumulative foreign currency translation adjustment $ 1,567 $ 2,457 Defined benefit pension obligation ( 364 ) ( 364 ) Accumulated other comprehensive income $ 1,203 $ 2,093

Leases (Tables)

Leases (Tables)	9 Months Ended
	Mar. 31, 2022
Leases [Abstract]
Schedule of Operating Lease Right-of-use Assets and Operating Lease Obligations	Operating lease right-of-use assets and operating lease obligations are represented in the table below (in thousands): March 31, June 30, Beginning balance operating lease right-of-use asset $ 22,522 $ 28,647 Lease asset added 1,486 1,069 Amortization for the year ( 6,157 ) ( 7,194 ) Ending balance operating lease right-of-use asset $ 17,851 $ 22,522 Beginning balance operating lease obligation $ 25,610 $ 32,397 Lease liability added 1,486 1,069 Repayment and interest accretion ( 6,816 ) ( 7,856 ) Ending balance operating lease obligation $ 20,280 $ 25,610 Current portion of operating lease obligation $ 8,351 $ 8,169 Noncurrent portion of operating lease obligation $ 11,929 $ 17,441
Schedule of Maturities of Operating Lease Liabilities	Maturities of operating lease liabilities as of March 31, 2022 are presented in the table below (in thousands): Year Ending June 30, Amount 2022 (remaining 3 months) $ 2,454 2023 9,321 2024 6,437 2025 3,445 2026 91 Thereafter — Total operating lease payments 21,748 Less: imputed interest ( 1,466 ) Present value of operating lease liabilities $ 20,282 Weighted average remaining lease term (in years) 2.50 Weighted average discount rate 5.67 %

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	9 Months Ended
	Mar. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of goodwill	Activity related to goodwill consisted of the following (in thousands): March 31, June 30, Balance at the beginning of the period $ 57,960 $ 57,717 Currency translation 40 243 Balance at the end of the period $ 58,000 $ 57,960
Schedule of carrying amount of acquired intangible assets, net	The Company’s carrying amount of acquired intangible assets, net, is as follows (in thousands): March 31, 2022 June 30, 2021 Useful Gross Accumulated Net Gross Accumulated Net (in years) Patent license 2 - 7 $ 1,170 $ ( 884 ) $ 286 $ 1,170 $ ( 735 ) $ 435
Schedule of estimated future amortization expense of acquired intangible assets	The estimated future amortization expense of acquired intangible assets as of March 31, 2022 is as follows (in thousands): Year Ending June 30, Amount 2022 (remaining 3 months) $ 36 2023 143 2024 107 2025 — $ 286

Derivative Financial Instrume_2

Derivative Financial Instruments (Tables)	9 Months Ended
	Mar. 31, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Summary of outstanding forward currency exchange contracts	As of March 31, 2022 and June 30, 2021, the Company had the following outstanding forward currency exchange contracts (in notional amount): March 31, As of June 30, (In thousands and U.S. dollars) 2022 2021 Canadian Dollar $ 2,171 $ 527 Swiss Franc 30,521 8,891 Chinese Yuan 687 1,927 Euro 3,862 19,037 British Pound 863 3,191 Indian Rupee 3,328 7,825 Japanese Yen 8,126 12,803 $ 49,558 $ 54,201
Schedule of gain (loss) associated with the Company's derivative financial instruments	The following table provides information about gain (loss) associated with the Company’s derivative financial instruments (in thousands): Three Months Ended Nine Months Ended 2022 2021 2022 2021 Foreign currency exchange gain (loss) on forward contracts $ ( 234 ) $ 108 $ ( 860 ) $ ( 1,055 ) Foreign currency transactions gain (loss) ( 172 ) ( 134 ) ( 947 ) 490

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Mar. 31, 2022
Fair Value Disclosures [Abstract]
Summary of carrying values and estimated fair values of short-term and long-term debt	The following table summarizes the carrying value and estimated fair value of the Term Loan, the Revolving Credit Facility, the 3.75 % Convertible Notes due 2022 and the 3.75% Convertible Notes due 2026 (in thousands): March 31, June 30, Carrying Fair Carrying Fair 3.75 % Convertible Notes Due 2022 $ 2,858 $ 2,814 $ 2,712 $ 3,164 3.75 % Convertible Notes Due 2026 97,481 98,312 72,388 108,163 Term Loan Facility 75,908 75,908 78,697 78,697 Revolving Credit Facility 5,000 5,000 20,000 20,000 Total $ 181,247 $ 182,034 $ 173,797 $ 210,024

Debt (Tables)

Debt (Tables)	9 Months Ended
	Mar. 31, 2022
Debt Disclosure [Abstract]
Schedule of Carrying Values of all Debt	The following table presents the carrying value of the Notes (as defined below), the Revolving Credit Facility and the Term Loan (in thousands): As of March 31, 2022 Revolving 3.75% 3.75% Term Loan Total Principal amount of the Notes $ 5,000 $ 2,865 $ 100,000 $ 77,000 $ 184,865 Unamortized debt costs — ( 7 ) ( 2,519 ) ( 1,092 ) ( 3,618 ) Net carrying amount $ 5,000 $ 2,858 $ 97,481 $ 75,908 $ 181,247 Reported as: Short-term debt $ 8,051 Long-term debt 173,196 Total debt $ 181,247 As of June 30, 2021 Revolving 3.75% 3.75% Term Loan Total Carrying amount of equity conversion component $ — $ 134 $ 25,944 $ — $ 26,078 Principal amount of the Notes $ 20,000 $ 2,865 $ 100,000 $ 80,000 $ 202,865 Unamortized debt costs — ( 34 ) ( 2,175 ) ( 1,303 ) ( 3,512 ) Unamortized debt discount — ( 119 ) ( 25,437 ) — ( 25,556 ) Net carrying amount $ 20,000 $ 2,712 $ 72,388 $ 78,697 $ 173,797 Reported as: Short-term debt $ 3,790 Long-term debt 170,007 Total debt $ 173,797
Summary of Interest Expense on Notes and Credit Facilities	A summary of interest expense on the Notes and Credit Facilities is as follows (in thousands): Three Months Ended Nine Months Ended 2022 2021 2022 2021 Interest expense related to contractual interest coupon $ 1,748 $ 2,678 $ 5,466 $ 8,259 Interest expense related to amortization of debt discount — 1,266 — 3,757 Interest expense related to amortization of debt issuance 215 370 594 1,086 $ 1,963 $ 4,314 $ 6,060 $ 13,102

Share-Based Compensation (Table

Share-Based Compensation (Tables)	9 Months Ended
	Mar. 31, 2022
Share-based Payment Arrangement [Abstract]
Summary of Share-based Compensation Expenses by Functional Line Item Noted Within Company's Operating Expenses	The following table presents details of share-based compensation expenses by functional line item noted within the Company's operating expenses (in thousands): Three Months Ended Nine Months Ended 2022 2021 2022 2021 Cost of revenue $ 388 $ 345 $ 1,192 $ 949 Research and development 317 324 1,037 1,023 Selling and marketing 598 379 1,614 1,060 General and administrative 1,397 1,441 4,068 4,065 $ 2,700 $ 2,489 $ 7,911 $ 7,097

Net Income (Loss) Per Common _2

Net Income (Loss) Per Common Share (Tables)	9 Months Ended
	Mar. 31, 2022
Earnings Per Share [Abstract]
Schedule of reconciliation of the numerator and denominator used in the calculation of basic and diluted net income (loss) per common share	A reconciliation of the numerator and denominator used in the calculation of basic and diluted net income (loss) per common share follows (in thousands): Three Months Ended Nine Months Ended 2022 2021 2022 2021 Numerator: Net income (loss) $ ( 1,046 ) $ ( 390 ) $ ( 1,895 ) $ 4,781 Denominator: Weighted average shares outstanding - basic 92,761 93,123 91,780 92,106 Dilutive effect of potential common shares — — — 1,316 Weighted average shares outstanding - diluted 92,761 93,123 91,780 93,422 Basic net income (loss) per share $ ( 0.01 ) $ ( 0.00 ) $ ( 0.02 ) $ 0.05 Diluted net income (loss) per share $ ( 0.01 ) $ ( 0.00 ) $ ( 0.02 ) $ 0.05
Schedule of all potentially dilutive securities excluded from the computation of basic and diluted net income per common share	The following table sets forth all potentially dilutive securities excluded from the computation in the table above because their effect would have been anti-dilutive (in thousands): As of March 31, 2022 2021 Stock options 6,317 6,742 RSUs, PSUs and MSUs 4,422 3,076 10,739 9,818

Segment Information (Tables)

Segment Information (Tables)	9 Months Ended
	Mar. 31, 2022
Segment Reporting [Abstract]
Summary of Revenue by Geographic Region	Revenues attributed to a country or region is based on the shipping addresses of the Company’s customers. The following summarizes revenue by geographic region (in thousands): Three Months Ended Nine Months Ended 2022 2021 2022 2021 Americas $ 25,410 $ 25,062 $ 100,362 $ 78,418 Europe, Middle East, India and Africa 29,550 30,826 93,581 87,424 Asia Pacific, excluding Japan and China 8,871 3,658 22,690 17,239 Japan 11,751 13,869 33,512 41,386 China 20,587 29,147 69,741 60,886 Total $ 96,169 $ 102,562 $ 319,886 $ 285,353
Schedule of Geographic Areas in Which the Company has Long Lived Tangible Assets	Information regarding geographic areas in which the Company has long-lived tangible assets is as follows (in thousands): March 31, June 30, 2022 2021 Americas $ 10,468 $ 10,588 Europe, Middle East, India and Africa 269 265 Asia Pacific, excluding Japan and China 325 170 Japan 376 701 China 782 608 Total $ 12,220 $ 12,332

Joint Venture (Tables)

Joint Venture (Tables)	9 Months Ended
	Mar. 31, 2022
Equity Method Investments and Joint Ventures [Abstract]
Summary of Financial Information of Joint Ventures (Operations Data)	Summarized financial information of the JV is based one-quarter lag due to the timing of the availability of the JV’s financial records is as follows (in thousands): Nine Months Ended December 31, 2021 Nine Months Ended December 31, 2020 Statement of Operations Data: Revenue $ 44,819 $ 28,095 Gross Profit 13,590 8,864 Net income 1,511 2,089 Net income attributable to the Company 740 1,021
Summary of Financial Information of Joint Ventures (Balance Sheet Data)	As of As of Summarized Balance Sheet Data: Assets Current assets $ 62,328 $ 19,895 Non current assets 22,136 22,446 $ 84,464 $ 42,341 Liabilities and Stockholders' Equity Current liabilities $ 52,085 $ 11,810 Non current liabilities 1,001 1,131 Stockholder's equity 31,378 29,400 $ 84,464 $ 42,341

Recent Accounting Pronounceme_3

Recent Accounting Pronouncements - Additional Information (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Jul. 01, 2021	Jun. 30, 2021	May 31, 2021
Increase to accumulated deficit	$ (489,070)		$ (488,024)
Decrease to additional paid in capital	$ 539,383		$ 554,680
Accounting Standards Update 2020-06
Increase to accumulated deficit		$ 800
Decrease to additional paid in capital		25,600
Increase to convertible debt, current		$ 24,800
3.75% Convertible Notes Due June 2026
Interest rate (as a percent)	3.75%	3.75%	3.75%	3.75%

Revenue - Summary of Contract w

Revenue - Summary of Contract with Customer, Asset and Liability (Details) - USD ($) $ in Thousands		Mar. 31, 2022	Jun. 30, 2021
Contract Assets:
Unbilled accounts receivable - current	[1]	$ 8,204	$ 12,354
Interest receivable - current	[2]	547	512
Long-term accounts receivable	[3]	4,906	4,970
Interest receivable - non-current	[3]	762	1,083
Contract Liabilities:
Customer advances		24,363	24,937
Deferred revenue – current		76,732	81,660
Deferred revenue – non-current		$ 24,550	$ 23,685
[1]	Included in accounts receivable on the Company’s consolidated balance sheet
[2]	Included in prepaid expenses and other current assets on the Company’s consolidated balance sheet
[3]	Included in other assets on the Company’s consolidated balance sheet

Revenue - Additional Informatio

Revenue - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021	Jun. 30, 2021
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Recognition of deferred revenue	$ 12.5	$ 6.5	$ 71.2	$ 23.7
Remaining performance obligations amount	1,121.8		$ 1,121.8
Percentage of changes in operating results on entity's revenue			29.00%
Capitalized costs to obtain a contract	10.7		$ 10.7		$ 8.9
Impairment loss	0.1	0.2	0.4	0.5
Capitalized contract cost, amortization	1	$ 0.8	2.8	$ 2
Long-term Warranty and Service
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Remaining performance obligations amount	70.1		70.1
Performance Obligations Other Than Warrant
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Remaining performance obligations amount	$ 1,051.7		$ 1,051.7

Revenue - Schedule of Remaining

Revenue - Schedule of Remaining Performance Obligations related to Warranty (Details) - Long-term Warranty and Service $ in Thousands	Mar. 31, 2022USD ($)
2022	$ 8,596
2023	28,337
2024	18,202
Thereafter	$ 14,993

Revenue - Additional Informat_2

Revenue - Additional Information (Details1) - Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2022-01-01	Mar. 31, 2022
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Remaining performance obligations recognized period	12 months
Minimum
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Remaining performance obligations percentage	19.00%
Maximum
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Remaining performance obligations percentage	23.00%

Supplemental Financial Inform_3

Supplemental Financial Information - Additional Information (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021	Jun. 30, 2021
Financing receivables
Accounts receivable with contractual maturities of more than one year	$ 2,761,000		$ 2,761,000		$ 3,387,000
Adjustments to allowance for credit loss			900,000		900,000
Financing receivables, additions					200,000
Financing receivables, write-offs			0		$ 3,600,000
Property and equipment, net
Depreciation expense	$ 1,400,000	$ 1,500,000	$ 4,100,000	$ 4,700,000

Supplemental Financial Inform_4

Supplemental Financial Information - Summary of Financing Receivables (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Jun. 30, 2021
Financing receivables
Financing receivable	$ 6,162	$ 7,102
Allowance for credit loss	(943)	(943)
Total, net	5,219	6,159
Current	2,458	2,772
Non-current	$ 2,761	$ 3,387

Supplemental Financial Inform_5

Supplemental Financial Information - Summary of Inventories (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Jun. 30, 2021
Inventory, Net [Abstract]
Raw materials	$ 56,804	$ 45,301
Work-in-process	17,642	22,014
Finished goods	63,073	58,614
Inventories	$ 137,519	$ 125,929

Supplemental Financial Inform_6

Supplemental Financial Information - Schedule of Property and Equipment, Net (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Jun. 30, 2021
Property and equipment, net
Property and equipment, gross	$ 90,962	$ 90,507
Less: Accumulated depreciation	(78,742)	(78,175)
Property and equipment, net	12,220	12,332
Furniture and Fixtures
Property and equipment, net
Property and equipment, gross	1,783	1,636
Computer and Office Equipment
Property and equipment, net
Property and equipment, gross	8,677	8,972
Software
Property and equipment, net
Property and equipment, gross	5,374	7,477
Leasehold Improvements
Property and equipment, net
Property and equipment, gross	26,674	26,102
Machinery and Equipment
Property and equipment, net
Property and equipment, gross	46,411	45,265
Construction in Progress
Property and equipment, net
Property and equipment, gross	$ 2,043	$ 1,055

Supplemental Financial Inform_7

Supplemental Financial Information - Accumulated Other Comprehensive Income (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Jun. 30, 2021
Accumulated Other Comprehensive Income (Loss)
Cumulative foreign currency translation adjustment	$ 1,567	$ 2,457
Defined benefit pension obligation	(364)	(364)
Accumulated other comprehensive income	$ 1,203	$ 2,093

Leases - Additional Information

Leases - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Leases [Abstract]
Operating lease costs	$ 2.3	$ 2.2	$ 7	$ 6.8
Short-term operating lease costs	0.1	0.1	0.3	0.3
Cash paid for amounts included in the measurement of operating lease liabilities	2.4	2.4	7.3	7.2
Operating lease liabilities arising from obtaining operating right of-use assets	$ 0.5	$ 0.2	$ 1.5	$ 0.8

Leases - Schedule of Operating

Leases - Schedule of Operating Lease Right-of-use Assets and Operating Lease Obligations (Details) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Mar. 31, 2022	Jun. 30, 2021
Leases [Abstract]
Beginning balance operating lease right-of-use asset	$ 22,522	$ 28,647
Lease asset added	1,486	1,069
Amortization for the year	(6,157)	(7,194)
Ending balance operating lease right-of-use asset	17,851	22,522
Beginning balance operating lease obligation	25,610	32,397
Lease liability added	1,486	1,069
Repayment and interest accretion	(6,816)	(7,856)
Ending balance operating lease obligation	20,280	25,610
Operating lease liabilities, current	8,351	8,169
Operating lease liabilities, non-current	$ 11,929	$ 17,441

Leases - Schedule of Maturities

Leases - Schedule of Maturities of Operating Lease Liabilities (Details) $ in Thousands	Mar. 31, 2022USD ($)
Leases [Abstract]
2022 (remaining 3 months)	$ 2,454
2023	9,321
2024	6,437
2025	3,445
2026	91
Thereafter	0
Total operating lease payments	21,748
Less: imputed interest	(1,466)
Present value of operating lease liabilities	$ 20,282
Weighted average remaining lease term (in years)	2 years 6 months
Weighted average discount rate	5.67%

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets - Schedule of Goodwill (Details) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Mar. 31, 2022	Jun. 30, 2021
Changes in the carrying amount of goodwill
Balance at the beginning of the period	$ 57,960	$ 57,717
Currency translation	40	243
Balance at the end of the period	$ 58,000	$ 57,960

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets - Additional Information (Details) - USD ($)	3 Months Ended				9 Months Ended		12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2022	Mar. 31, 2021	Jun. 30, 2017
Finite Lived Intangible Assets [Line Items]
Impairment of goodwill		$ 0
Amortization expense	$ 40,000		$ 60,000		$ 200,000	$ 200,000
Patent license
Finite Lived Intangible Assets [Line Items]
Purchase of intangible assets				$ 170,000
Useful Lives				2 years			7 years

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets - Schedule of Carrying Amount of Acquired Intangible Assets, Net (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended	12 Months Ended
	Mar. 31, 2020	Mar. 31, 2022	Jun. 30, 2017	Jun. 30, 2021
Finite Lived Intangible Assets [Line Items]
Net Amount		$ 286		$ 435
Patent license
Finite Lived Intangible Assets [Line Items]
Useful Lives	2 years		7 years
Gross Carrying Amount		1,170		1,170
Accumulated Amortization		(884)		(735)
Net Amount		$ 286		$ 435
Patent license | Minimum
Finite Lived Intangible Assets [Line Items]
Useful Lives		2 years
Patent license | Maximum
Finite Lived Intangible Assets [Line Items]
Useful Lives		7 years

Goodwill and Intangible Asset_5

Goodwill and Intangible Assets - Schedule of Estimated Future Amortization Expense of Acquired Intangible Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Jun. 30, 2021
Estimated future amortization expense of purchased intangible assets
2022 (remaining 6 months)	$ 36
2023	143
2024	107
Net Amount	$ 286	$ 435

Derivative Financial Instrume_3

Derivative Financial Instruments - Summary of Outstanding Forward Currency Exchange Contracts (Details) - Forward Currency Exchange Contracts - USD ($)	Mar. 31, 2022	Jun. 30, 2021
Outstanding forward currency exchange contracts	$ 49,558,000	$ 54,201,000
Canadian Dollar
Outstanding forward currency exchange contracts	2,171,000	527,000
Swiss Franc
Outstanding forward currency exchange contracts	30,521,000	8,891,000
Chinese Yuan
Outstanding forward currency exchange contracts	687,000	1,927,000
Euro
Outstanding forward currency exchange contracts	3,862,000	19,037,000
British Pound
Outstanding forward currency exchange contracts	863,000	3,191,000
Indian Rupee
Outstanding forward currency exchange contracts	3,328,000	7,825,000
Japanese Yen
Outstanding forward currency exchange contracts	$ 8,126,000	$ 12,803,000

Derivative Financial Instrume_4

Derivative Financial Instruments - Schedule of Gain (Loss) Associated with the Company's Derivative Financial Instruments (Details) - Other expense, net - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Foreign currency exchange gain (loss) on forward contracts	$ (172)	$ (134)	$ (947)	$ 490
Forward contracts
Foreign currency exchange gain (loss) on forward contracts	$ (234)	$ 108	$ (860)	$ (1,055)

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Details) - USD ($)	Mar. 31, 2022	Jun. 30, 2021	May 31, 2021	Mar. 31, 2021	Aug. 31, 2017
3.75% Convertible Notes Due 2022
Financial assets
Interest rate (as a percent)	3.75%	3.75%	3.75%	3.75%	3.75%
Forward Currency Exchange Contracts
Financial assets
Outstanding forward currency exchange contracts	$ 49,558,000	$ 54,201,000
Forward Currency Exchange Contracts | Level 1
Financial assets
Fair value of currency contract based on exchange rate	$ 49,600,000	$ 54,200,000

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Carrying Value and Estimated Fair Value of all Debt (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Jun. 30, 2021
Carrying Value
Fair value measurement
Long term debt	$ 181,247	$ 173,797
Fair Value
Fair value measurement
Long term debt	182,034	210,024
Non-recurring basis | Carrying Value | Level 2 | 3.75% Convertible Notes Due 2022
Fair value measurement
Long term debt	2,858	2,712
Non-recurring basis | Carrying Value | Level 2 | 3.75% Convertible Notes Due 2026
Fair value measurement
Long term debt	97,481	72,388
Non-recurring basis | Fair Value | Level 2 | 3.75% Convertible Notes Due 2022
Fair value measurement
Long term debt	2,814	3,164
Non-recurring basis | Fair Value | Level 2 | 3.75% Convertible Notes Due 2026
Fair value measurement
Long term debt	98,312	108,163
Term Loan Facility | Non-recurring basis | Carrying Value | Level 2
Fair value measurement
Long term debt	75,908	78,697
Term Loan Facility | Non-recurring basis | Fair Value | Level 2
Fair value measurement
Long term debt	75,908	78,697
Revolving Credit Facility | Non-recurring basis | Carrying Value | Level 2
Fair value measurement
Long term debt	5,000	20,000
Revolving Credit Facility | Non-recurring basis | Fair Value | Level 2
Fair value measurement
Long term debt	$ 5,000	$ 20,000

Fair Value Measurements - Sum_2

Fair Value Measurements - Summary of Carrying Value and Estimated Fair Value of all Debt (Parenthetical) (Details)	Mar. 31, 2022	Jul. 01, 2021	Jun. 30, 2021	May 31, 2021	Mar. 31, 2021	Aug. 31, 2017
3.75% Convertible Notes Due 2022
Fair value measurement
Interest rate (as a percent)	3.75%		3.75%	3.75%	3.75%	3.75%
3.75% Convertible Notes Due 2026
Fair value measurement
Interest rate (as a percent)	3.75%	3.75%	3.75%	3.75%

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021	Jun. 30, 2021
License agreement | WARF (Wisconsin Alumni Research Foundation)
Loss Contingencies [Line Items]
Royalty costs	$ 0.3	$ 0.4	$ 1.2	$ 1.3
Royalty amount accrued	2.2		2.2		$ 2.3
Financial Guarantee | Various Customers
Loss Contingencies [Line Items]
Bank guarantees	$ 0.9		$ 0.9		$ 1.2

Debt - Additional Information (

Debt - Additional Information (Details)	Jul. 01, 2021USD ($)	May 06, 2021USD ($)	May 31, 2021USD ($)	Jun. 30, 2021USD ($)	Mar. 31, 2022USD ($)$ / shares	Mar. 31, 2021USD ($)	Jun. 30, 2021USD ($)	May 14, 2021USD ($)	Aug. 31, 2017USD ($)	Apr. 30, 2014	Feb. 28, 2013
Debt Instrument [Line Items]
Increase to accumulated deficit				$ (488,024,000)	$ (489,070,000)		$ (488,024,000)
Decrease to additional paid in capital				554,680,000	539,383,000		554,680,000
Debt discount costs				25,556,000			25,556,000
Principal prepayment of term loan					0	$ 10,500,000
Principal amount of the Notes				202,865,000	184,865,000		202,865,000
Unamortized debt costs				3,512,000	3,618,000		3,512,000
Revolving Credit Facility
Debt Instrument [Line Items]
Initial borrowings								$ 25,000,000
Principal amount of the Notes				20,000,000	5,000,000		20,000,000
Unamortized debt costs				1,300,000	1,100,000		1,300,000
Term Loan
Debt Instrument [Line Items]
Principal amount of the Notes				80,000,000	$ 77,000,000		80,000,000
3.75% Convertible Notes Due 2022
Debt Instrument [Line Items]
Aggregate principal amount of debt issued				$ 82,100,000			$ 82,100,000		$ 85,000,000
Interest rate (as a percent)			3.75%	3.75%	3.75%	3.75%	3.75%		3.75%
Conversion rate, number of shares to be issued per $1000 of principal amount (in shares)					174.8252
Principal amount used for debt instrument conversion ratio					$ 1,000
Conversion price (in dollars per share) | $ / shares					$ 5.72
Repurchase price, as a percentage of the principal amount, in the event of a fundamental change, as defined in Indenture					100.00%
Convertible notes exchanged			$ 82,100,000
Convertible notes, aggregate principal amount outstanding				$ 2,900,000	$ 2,900,000		$ 2,900,000
Loss on extinguishment of debt							4,300,000
Extinguishment of equity component							14,500,000
Settlement consideration paid							96,000,000
Debt instrument, fair value of liability component				81,500,000			81,500,000
Debt discount costs				119,000			119,000
Principal amount of the Notes				2,865,000	2,865,000		2,865,000
Unamortized debt costs				$ 34,000	$ 7,000		$ 34,000
3.50% Convertible Notes Due 2018
Debt Instrument [Line Items]
Interest rate (as a percent)											3.50%
3.50% Series A Convertible Senior Notes Due 2018
Debt Instrument [Line Items]
Interest rate (as a percent)										3.50%
3.75% Convertible Notes Due 2026
Debt Instrument [Line Items]
Aggregate principal amount of debt issued			$ 100,000,000
Interest rate (as a percent)	3.75%		3.75%	3.75%	3.75%		3.75%
Conversion rate, number of shares to be issued per $1000 of principal amount (in shares)					170.5611
Principal amount used for debt instrument conversion ratio					$ 1,000
Conversion price (in dollars per share) | $ / shares					$ 5.86
Repurchase price, as a percentage of the principal amount, in the event of a fundamental change, as defined in Indenture					100.00%
Convertible notes exchanged			$ 97,100,000
Convertible notes, aggregate principal amount outstanding				$ 100,000,000	$ 100,000,000		$ 100,000,000
Convertible notes, aggregate principal amount issued for cash			$ 2,900,000
Debt discount costs				25,437,000			25,437,000
Principal amount of the Notes				100,000,000	100,000,000		100,000,000
Unamortized debt costs				$ 2,175,000	$ 2,519,000		$ 2,175,000
3.75% Convertible Notes Due 2026 | New Qualified Investors
Debt Instrument [Line Items]
Interest rate (as a percent)	3.75%				3.75%
Extinguishment of equity component					$ 25,900,000
Debt instrument, fair value of liability component					74,100,000
Convertible notes, aggregate principal amount issued for cash					2,900,000
Reduction in debt issuance cost allocated to additional paid in capital					$ 700,000
Increase to accumulated deficit	$ 800,000
Decrease to additional paid in capital	25,600,000
Increase to convertible debt, current	$ 24,800,000
Accounting Standards Update [Extensible Enumeration]	http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate202006Member
3.75% Convertible Notes due 2022 and 3.75% Convertible Notes due 2026
Debt Instrument [Line Items]
Interest rate (as a percent)					3.75%
Discounts, issuance costs and third party costs					$ 25,600,000
Issuance costs attributable to liability component amortized					$ 800,000
Exchange | 3.75% Convertible Notes Due 2022
Debt Instrument [Line Items]
Aggregate principal amount of debt issued									$ 53,000,000
Exchange | 3.50% Convertible Notes due 2018 and 3.5% Series A Senior Notes due 2018
Debt Instrument [Line Items]
Aggregate principal amount of debt issued									47,000,000
Repurchase
Debt Instrument [Line Items]
Repurchase/Retirement of existing notes									28,000,000
Repurchase | 3.75% Convertible Notes Due 2022
Debt Instrument [Line Items]
Aggregate principal amount of debt issued									$ 32,000,000
Senior Secured Credit Agreement | Consolidated Senior Net Leverage Ratio is Greater Than or Equal to 3.00:1.00
Debt Instrument [Line Items]
Variable rate (as a percent)		3.25%
Senior Secured Credit Agreement | Consolidated Senior Net Leverage Ratio is Greater Than or Equal to 2.00:1.00 But Less Than 3.00:1.00
Debt Instrument [Line Items]
Variable rate (as a percent)		3.00%
Senior Secured Credit Agreement | Consolidated Senior Net Leverage Ratio is Greater Than or Equal to 1.00:1.00 But Less Than 2.00:1.00
Debt Instrument [Line Items]
Variable rate (as a percent)		2.75%
Senior Secured Credit Agreement | Consolidated Senior Net Leverage Ratio is Less Than 1.00:1.00
Debt Instrument [Line Items]
Variable rate (as a percent)		2.50%
Senior Secured Credit Agreement | Revolving Credit Facility
Debt Instrument [Line Items]
Credit facility borrowing capacity		$ 40,000,000
Senior Secured Credit Agreement | Term Loan
Debt Instrument [Line Items]
Term of loan		5 years
Credit facility borrowing capacity		$ 80,000,000
Senior Secured Credit Agreement | Credit Agreement
Debt Instrument [Line Items]
Unused commitment fee percentage per annum of average unused portion of the New Revolving Credit Facility				0.35%
Senior Secured Credit Agreement | Credit Agreement | Consolidated Senior Net Leverage Ratio is Greater Than or Equal to 3.00:1.00
Debt Instrument [Line Items]
Unused commitment fee percentage per annum of average unused portion of the New Revolving Credit Facility		0.40%
Senior Secured Credit Agreement | Credit Agreement | Consolidated Senior Net Leverage Ratio is Greater Than or Equal to 2.00:1.00 But Less Than 3.00:1.00
Debt Instrument [Line Items]
Unused commitment fee percentage per annum of average unused portion of the New Revolving Credit Facility		0.35%
Senior Secured Credit Agreement | Credit Agreement | Consolidated Senior Net Leverage Ratio is Greater Than or Equal to 1.00:1.00 But Less Than 2.00:1.00
Debt Instrument [Line Items]
Unused commitment fee percentage per annum of average unused portion of the New Revolving Credit Facility		0.30%
Senior Secured Credit Agreement | Credit Agreement | Consolidated Senior Net Leverage Ratio is Less Than 1.00:1.00
Debt Instrument [Line Items]
Unused commitment fee percentage per annum of average unused portion of the New Revolving Credit Facility		0.25%
Senior Secured Credit Agreement | Credit Agreement | If all or Portion of Loans Under New Term Loan Facility are Prepaid
Debt Instrument [Line Items]
Unused commitment fee percentage per annum of average unused portion of the New Revolving Credit Facility		1.00%
Senior Secured Credit Agreement | 90-day LIBOR
Debt Instrument [Line Items]
Interest rate determination basis					90-day LIBOR
Variable rate (as a percent)				3.00%
Senior Secured Credit Agreement | 90-day LIBOR | Floor Rate
Debt Instrument [Line Items]
Variable rate (as a percent)		0.50%

Debt - Schedule of Carrying Val

Debt - Schedule of Carrying Values of All Debt (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Jun. 30, 2021
Debt Instrument [Line Items]
Carrying amount of equity conversion component		$ 26,078
Principal amount of the Notes	$ 184,865	202,865
Unamortized debt costs	(3,618)	(3,512)
Unamortized debt discount		(25,556)
Net carrying amount	181,247	173,797
Reported as:
Short-term debt	8,051	3,790
Long-term debt	173,196	170,007
Net carrying amount	181,247	173,797
Revolving Credit Facility
Debt Instrument [Line Items]
Principal amount of the Notes	5,000	20,000
Unamortized debt costs	(1,100)	(1,300)
Net carrying amount	5,000	20,000
Reported as:
Net carrying amount	5,000	20,000
3.75% Convertible Notes Due 2022
Debt Instrument [Line Items]
Carrying amount of equity conversion component		134
Principal amount of the Notes	2,865	2,865
Unamortized debt costs	(7)	(34)
Unamortized debt discount		(119)
Net carrying amount	2,858	2,712
Reported as:
Net carrying amount	2,858	2,712
3.75% Convertible Notes Due 2026
Debt Instrument [Line Items]
Carrying amount of equity conversion component		25,944
Principal amount of the Notes	100,000	100,000
Unamortized debt costs	(2,519)	(2,175)
Unamortized debt discount		(25,437)
Net carrying amount	97,481	72,388
Reported as:
Net carrying amount	97,481	72,388
Term Loan Facility due December 2022
Debt Instrument [Line Items]
Principal amount of the Notes	77,000	80,000
Unamortized debt costs	(1,092)	(1,303)
Net carrying amount	75,908	78,697
Reported as:
Net carrying amount	$ 75,908	$ 78,697

Debt - Summary of Interest Expe

Debt - Summary of Interest Expense on Notes and Credit Facilities (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Debt Disclosure [Abstract]
Interest expense related to contractual interest coupon	$ 1,748	$ 2,678	$ 5,466	$ 8,259
Interest expense related to amortization of debt discount		1,266		3,757
Interest expense related to amortization of debt issuance costs	215	370	594	1,086
Total	$ 1,963	$ 4,314	$ 6,060	$ 13,102

Share-Based Compensation - Summ

Share-Based Compensation - Summary of Share-Based Compensation Expenses by Functional Line Item Noted Within Company's Operating Expenses (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Share-based compensation expenses
Share-based compensation expense	$ 2,700	$ 2,489	$ 7,911	$ 7,097
Cost of revenue
Share-based compensation expenses
Share-based compensation expense	388	345	1,192	949
Research and development
Share-based compensation expenses
Share-based compensation expense	317	324	1,037	1,023
Selling and marketing
Share-based compensation expenses
Share-based compensation expense	598	379	1,614	1,060
General and administrative
Share-based compensation expenses
Share-based compensation expense	$ 1,397	$ 1,441	$ 4,068	$ 4,065

Net Income (Loss) Per Common _3

Net Income (Loss) Per Common Share - Schedule of reconciliation of the numerator and denominator used in the calculation of basic and diluted net income (loss) per common share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended						9 Months Ended
	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Sep. 30, 2020	Mar. 31, 2022	Mar. 31, 2021
Numerator:
Net income	$ (1,046)	$ 179	$ (1,028)	$ (390)	$ 4,769	$ 402	$ (1,895)	$ 4,781
Denominator:
Weighted average shares outstanding - basic	92,761,000			93,123,000			91,780,000	92,106,000
Dilutive effect of potential common shares	0			0			0	1,316,000
Weighted average shares outstanding - diluted	92,761,000			93,123,000			91,780,000	93,422,000
Basic net income (loss) per share	$ (0.01)			$ 0			$ (0.02)	$ 0.05
Diluted net income (loss) per share	$ (0.01)			$ 0			$ (0.02)	$ 0.05

Net Income (Loss) Per Common _4

Net Income (Loss) Per Common Share - Additional Information (Details) - shares shares in Millions	9 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Jul. 01, 2021	Jun. 30, 2021	May 31, 2021	Aug. 31, 2017
3.75% Convertible Senior Notes due 2022
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Interest rate (as a percent)	3.75%	3.75%		3.75%	3.75%	3.75%
Common stock not included in the calculation of potentially diluted shares	0.5	14.9
3.75% Convertible Notes Due June 2026
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Interest rate (as a percent)	3.75%		3.75%	3.75%	3.75%
Common stock not included in the calculation of potentially diluted shares	17.1

Net Income (Loss) Per Common _5

Net Income (Loss) Per Common Share - Schedule of all potentially dilutive securities excluded from the computation of basic and diluted net income per common share (Details) - shares shares in Thousands	9 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from the computation of diluted net income per share (in shares)	10,739	9,818
Stock options
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from the computation of diluted net income per share (in shares)	6,317	6,742
RSUs, PSUs and MSUs
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from the computation of diluted net income per share (in shares)	4,422	3,076

Segment Information - Additiona

Segment Information - Additional Information (Details)	9 Months Ended
	Mar. 31, 2022Segment
Segment Reporting [Abstract]
Number of operating segments	1
Number of reportable segments	1

Segment Information - Summary o

Segment Information - Summary of Revenue by Geographic Region (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Segment Information
Total net revenue	$ 96,169	$ 102,562	$ 319,886	$ 285,353
Americas
Segment Information
Total net revenue	25,410	25,062	100,362	78,418
Europe, Middle East, India and Africa
Segment Information
Total net revenue	29,550	30,826	93,581	87,424
Asia Pacific, excluding Japan and China
Segment Information
Total net revenue	8,871	3,658	22,690	17,239
Japan
Segment Information
Total net revenue	11,751	13,869	33,512	41,386
China
Segment Information
Total net revenue	$ 20,587	$ 29,147	$ 69,741	$ 60,886

Segment Information - Schedule

Segment Information - Schedule of Geographic Areas in Which the Company has Long-Lived Tangible Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Jun. 30, 2021
Segment Information
Long lived tangible assets	$ 12,220	$ 12,332
Americas
Segment Information
Long lived tangible assets	10,468	10,588
Europe, Middle East, India and Africa
Segment Information
Long lived tangible assets	269	265
Asia Pacific, excluding Japan and China
Segment Information
Long lived tangible assets	325	170
Japan
Segment Information
Long lived tangible assets	376	701
China
Segment Information
Long lived tangible assets	$ 782	$ 608

Joint Venture - Additional Info

Joint Venture - Additional Information (Details) - USD ($)	3 Months Ended			9 Months Ended		12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021	Jun. 30, 2021	Jun. 30, 2020	Jan. 31, 2019
Schedule Of Equity Method Investments [Line Items]
Accumulated deficit	$ 489,070,000			$ 489,070,000		$ 488,024,000
Investee's currency translation adjustment				40,000		243,000
Proportional share of underlying equity in net assets, difference amount	1,000			1,000
Goodwill	$ 58,000,000			$ 58,000,000		57,960,000	$ 57,717,000
Impairment of goodwill		$ 0
Accuray Asia
Schedule Of Equity Method Investments [Line Items]
Percentage of ownership interest in joint venture	49.00%			49.00%				49.00%
Deferred of intra-entity profit margin	$ 5,700,000			$ 5,700,000		$ 2,100,000
Previously deferred intra-entity margin from system sales	300,000		$ 400,000	1,500,000	$ 1,900,000
Deferral of intra entity margin from system sales	2,900,000		$ 800,000	5,000,000	$ 1,700,000
Accumulated deficit	1,500,000			1,500,000
Equity method investment	14,300,000			14,300,000
Proportional share of underlying equity in net assets	15,200,000			15,200,000
Investee's currency translation adjustment				1,100,000
Elimination of equity method investment intra-entity profit on sales	5,700,000
Goodwill	4,700,000			$ 4,700,000
Impairment of goodwill	$ 0

Joint Venture - Summary of Fina

Joint Venture - Summary of Financial Information of Joint Ventures (Operations Data) (Details) - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Sep. 30, 2020	Mar. 31, 2022	Dec. 31, 2021	Mar. 31, 2021	Dec. 31, 2020
Schedule Of Equity Method Investments [Line Items]
Total net revenue	$ 96,169			$ 102,562			$ 319,886		$ 285,353
Gross Profit	34,784			39,542			116,935		115,776
Net income	$ (1,046)	$ 179	$ (1,028)	$ (390)	$ 4,769	$ 402	$ (1,895)		$ 4,781
CNNC Accuray (Tianjin) Medical Technology Co. Ltd.
Schedule Of Equity Method Investments [Line Items]
Total net revenue								$ 44,819		$ 28,095
Gross Profit								13,590		8,864
Net income								1,511		2,089
Net income attributable to the Company								$ 740		$ 1,021

Joint Venture - Summary of Fi_2

Joint Venture - Summary of Financial Information of Joint Ventures (Balance Sheet Data) (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020
Schedule Of Equity Method Investments [Line Items]
Current assets	$ 347,196			$ 352,773
Total assets	469,436			480,098
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities	201,340			192,359
Stockholder's equity	51,609	$ 50,994	$ 45,765	68,840	$ 78,550	$ 77,778	$ 67,440	$ 63,635
Total liabilities and stockholders' equity	$ 469,436			$ 480,098
CNNC Accuray (Tianjin) Medical Technology Co. Ltd.
Schedule Of Equity Method Investments [Line Items]
Current assets		62,328				19,895
Non current assets		22,136				22,446
Total assets		84,464				42,341
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities		52,085				11,810
Non current liabilities		1,001				1,131
Stockholder's equity		31,378				29,400
Total liabilities and stockholders' equity		$ 84,464				$ 42,341

Income Tax - Additional Informa

Income Tax - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Income Taxes [Line Items]
Income tax expense	$ 407	$ 721	$ 1,318	$ 1,352
Gross unrecognized tax benefits	18,800		18,800
Uncertain tax benefits that, if realized, would affect the effective tax rate	18,600		$ 18,600
Subsequent period within which no material changes in unrecognized tax benefits are expected			12 months
Foreign
Income Taxes [Line Items]
Income tax expense	$ 400	$ 700	$ 1,300	$ 1,400